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ABSTRACT 
BACKGROUND 
Myeloproliferative Neoplasms (MPN) are a heterogeneous group of diseases that are characterized 
by clonal proliferation of the erythroid, myeloid, or megakaryocytic lineages. The discovery of the JAK2 
V617F mutation has provided new insights into the disease and has broadened the therapeutic 
landscape. The management of MPN is aimed at relieving symptoms of disease, managing and 
modifying the signs of disease, and preventing complications. There is a lack of data with regard to 
MPN in South Africa and this study attempts to understand this disease entity as represented by 
patients at a large public sector hospital. 
 
 
PATIENTS AND METHODS 
This study is a retrospective review of adult patients seen at the Clinical Haematology Unit, 
Department of Internal Medicine at Chris Hani Baragwanath Academic Hospital during the period 
01/01/1987 to 31/12/2011. The aim of the study was to determine the profile of patients diagnosed 
with Polycythaemia Vera (PV), Essential Thrombocythaemia (ET), and Primary Myelofibrosis (PMF), 
and in particular to describe the demographics, clinical presentation, management, and outcomes of 
patients with MPN. 
 
 
RESULTS AND DISCUSSION 
A total of 94 patients were analyzed of which 37% were diagnosed with ET, 18% were PV, and 45% 
PMF. The median age of presentation was 63, 54, and 64 for ET, PV, and PMF respectively with a 
female to male ratio of 1.24:1 for all patients. Fatigue, weight loss, and pruritus were the most 
common presenting symptoms, while splenomegaly was found in 80% of patients and was the 
predominant clinical manifestation. It was noted that hydroxyurea was the most important form of 
cytoreductive therapy used, especially in ET where 91% received it. Venesection was performed in 
100% of PV patients. JAK2 V617F mutation testing became available in 2006 and of all the patients 
tested, 100% (ET), and 89 %( PV), and 89 %( PMF) were positive. Only 5% of patients achieved a 
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complete response whilst on the treatment available. Transformation to acute myeloid leukaemia was 
shown in 9% of the patients, whilst 22% ultimately resulting in death. 
 
 
CONCLUSION 
Ph1 chromosome negative MPN in South Africa is an uncommon disease which most commonly occurs 
in the 55 to 65 year old age group. Overall, it is slightly more common in females compared to males, 
with particular reference to ET. PMF is the most common Ph1 chromosome negative MPN, followed 
by ET and PV. Patients with Ph1 chromosome negative MPN present typically with fatigue, 
constitutional symptoms and splenomegaly. Presentation to hospital with thrombotic events and 
bleeding was also significant. The mainstay of treatment is variable, depending on the nature of the 
MPN i.e. venesection for PV, and hydroxyurea for ET and PMF. Complications such as arterial and 
venous thrombosis, bleeding and leukaemic transformation occurred at a similar rate to that 
described in the literature. JAK2 V617F mutation investigation was available since 2005, and 93% of 
all patients that were tested, proved to have the mutation. More frequent and routine testing of this 
mutation is needed in the future. Other treatment options such as anagrelide, interferon alpha, and 
JAK inhibitors were used at a very low frequency in our population of MPN patients. The prognosis of 
patients correlates with other studies of MPN, with PMF showing the worst prognosis and lowest 
median overall survival rate, and the highest transformation rate to acute leukaemia. More 
widespread use of JAK2 inhibitors in the future may impact favourably on the adverse prognosis and 
poor survival.       
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CHAPTER 1: LITERATURE REVIEW 
1.1 INTRODUCTION 
In 1951, William Dameshek coined the term “Myeloproliferative Disorders (MPD)” as a clinico-
pathological entity which included chronic myelogenous leukaemia (CML), polycythaemia vera (PV), 
essential thrombocythaemia (ET), and primary myelofibrosis (PMF) (1). The word disorders in 
“myeloproliferative disorders” has now been replaced with the word “neoplasms”, according to the 
World Health Organization (WHO) classification of myeloproliferative neoplasms (MPN) published in 
2008 (2). 
The discovery of myeloid cells occurred as early as the 17th century when van Leeuwenhoek and 
Lieutaud described red cells and white cells respectively (3). The description of platelets was attributed 
to Alfred Donne in 1842 while Bizzozero was credited with their role in homeostasis (1). Before 
Dameshek, leukaemias were classified into myeloid and lymphoid subtypes by Paul Ehrlich in 1880, 
and the notion that a common stem cell gave rise to distinct cell lineages was shown (4).“Splenic 
Medullary Leukaemia” was a term used by Heuck in 1879 for 2 patients with an increased number of 
abnormal leucocytes and the presence of marrow fibrosis, which is now known as PMF (5). In 1892 a 
man presented to Dr Louis Henri Vaquez, with features of chronic “cyanosis”, hepatosplenomegaly, 
and marked erythrocytosis which he considered to be congenital heart disease (6). William Osler 
reviewed 18 similar cases in 1908 and referred to these as “Vaquez disease” or “polycythaemia with 
cyanosis, thus PV was first recognized (7). ET was the last of the MPN to be described in 1934 by 
Epstein and Goedel (1). The interrelationship between the MPN was supported by the discovery of 
post PV myelofibrosis in 1935 and this suggested that trilineage myeloproliferation arose from a 
common primitive reticulum cell (8). Substantial progress has been made since these early 
descriptions of the MPN and more exciting developments were to follow. 
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 Molecular and cytogenetic mechanisms of the MPN have been studied for many years. The 
identification of the fusion gene BCR/ABL and the t(9;22) translocation which generates the 
Philadelphia chromosome (Ph1) as the critical pathogenetic event in CML has led to a better 
understanding of this entity, as well as the development of specific therapy targeting the molecular 
defect (9). Hence the development of the tyrosine kinase inhibitor, imatinib , led to one of the most 
successful therapeutic agents in the history of haematological malignancies (10). Furthermore, in 
2005, the discovery of a point mutation in the Janus Kinase 2 (JAK2) gene in the majority of patients 
with Ph1 negative MPN were reported (11). The mutation was called the JAK2 V617F and further 
revolutionized our knowledge of the disease pathogenesis and led to redefining of diagnostic criteria. 
The MPN are a heterogeneous group of diseases that are characterized by increased proliferation of 
the erythroid, megakaryocytic or myeloid lineages. They are thought to arise from transformation of 
a haemopoetic stem cell. They are classified into 9 different entities, which includes the 4 common 
MPN i.e. CML, PV, ET, and PMF, as well as uncommon entities such as Chronic Neutrophilic Leukaemia, 
Chronic Eosinophilic Leukaemia, Hypereosinophilic Syndrome, Systemic Mastocytosis, and MPN 
Unclassifiable (12). The three major non-leukaemic, Ph1 negative disorders in this classification are 
PV, ET, and PMF. 
1.2 PATHOGENESIS 
The origins of MPN from a clone of haematopoietic stem cells was confirmed by Phillip Fialkow and 
colleagues in the 1960’s and 1970’s (13). Techniques demonstrating inactivation of the X-chromosome 
were performed on women with PV or ET, who carried a polymorphic variant of the X-linked glucose-
6-phosphate dehydrogenase gene (14). This suggested that some myeloid cells were clonally derived. 
The defining phenotype of these disorders thus includes an increased red cell mass in PV, an increased 
platelet count in ET, and fibrosis of the bone marrow in PMF. The subsequent discovery of the somatic 
mutation in the JAK2 gene further facilitated how a molecular defect was accountable for these 
disorders (15). 
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Normal haematopoiesis is dependent on the JAK-STAT (Janus Kinase and Signal Transducer and 
Activator of Transcription) pathway. The Janus Kinase (JAK) group consists of JAK1, JAK2, JAK3, and 
TYK2. Cytokine receptors, upon binding of cytokines, recruit and activate JAK kinases (16). This results 
in phosphorylation of downstream signalling pathways such as phosphoinositide 3-kinase (PI3), RAS, 
and transcription factors termed STATs ( signal transducers and activators of transcription) (16). JAK2 
is particularly involved in transducing intracellular signalling by the receptors for erythropoietin, 
thrombopoietin, interleukin 5, interleukin 3, and granulocyte-macrophage colony stimulating factor 
(17). STAT 3 and STAT 5 phosphorylation mediated by JAK2 leads to nuclear translocation of STAT 
heterodimers and homodimers, which bind to DNA sequences on genes that regulate cell 
proliferation, differentiation, and apoptosis (18). Aberrations in these pathways  have been shown to 
be the underlying cause for leukaemias and MPN (19). Since these MPN are closely related, transitional 
forms may exist, as well as evolution from one form to another (20).  
1.2.1 JAK2 V617F Mutation 
An acquired point mutation in the JAK2 gene was discovered in 2005, in the majority of patients with 
Ph1 negative MPN (21). This was a milestone in our understanding of Ph1 negative MPN. This mutation 
at codon 617 of the JAK2 protein is a guanine to thymidine transversion, which substitutes a 
phenylalanine for a valine (22). Studies have demonstrated that the mutation occurs in more than 95% 
of patients with PV, and in 50 to 60% of patients with ET or PMF (23). Most patients with MPN are 
heterozygous for JAK2 V617F, but there is a subset of patients, particularly with PV, that are 
homozygous for the JAK2 V617F allele (24). Homozygosity of JAK2 V617F results from acquired 
uniparental disomy at chromosomal locus 9p24. Also demonstrated in studies is the fact that 
homozygous subclones produce increased signalling and thus a more robust clinical and 
haematological picture, than the heterozygous subtype, particularly in patients with PV (24). It is also 
hypothesised that the level of JAK2 V617F kinase activity could determine the phenotype of the MPN 
(25). Therefore according to this hypotheses, low kinase activity would lead to thrombocythemia, 
while high levels of activity would to polycythaemia or myelofibrosis (26). 
 JAK2 is a cytoplasmic tyrosine kinase receptor involved in transducing intracellular signalling, as 
mentioned previously. The effects of the JAK2 V617F mutation are activation of STAT5, MAPK/ERK, 
and PI-3K/AKT signalling pathways (27). This thus causes further changes in the cell cycle, cell 
differentiation and apoptosis in a cytokine independent or hypersensitive manner. Promotion of the 
G1/S transition in haematopoietic cell lines occurs with upregulation of cyclin D2 and down regulation 
of p27 (28). The anti-apoptotic effect of the mutation is due to the overexpression of BCL-XI, as a 
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consequence of STAT5 activation (29). The net result is the production of a diverse range of proteins 
that promote cell survival and proliferation.  
Associations between the JAK2 V167F mutation and the clinical presentation of MPN have been 
documented. Patients with high mutational loads were shown to present more commonly with 
advancing age and were also more likely to suffer with life threatening complications (30). An 
increased thrombotic as well as bleeding risk were demonstrated (31). The incidence of progression 
to large splenomegaly, higher leucocyte counts, as well as transformation of the MPN to the fatal 
acute leukaemia was also increased in patients with the JAK2 V617F mutation, especially in patients 
with PMF (32). Conflicting results have been seen with regard to the impact of the mutation with 
overall survival (33). Some studies showed that the mutation had no impact, while others showed that 
patients with PMF and a positive JAK2 V617F mutation had poorer survival, but no consensus has been 
reached (33). 
The JAK2 V617F mutation has definitely led to a better understanding of the mechanism of the MPN 
process, but has also given us further knowledge on risk stratification, provided us with new tools of 
diagnosis of MPN, and ultimately has led to the trials and production of therapeutic options. Since 
2005, many JAK2 inhibitors have been developed, majority of which are being evaluated under clinical 
trials (34).  
Almost all patients with PV have been shown to be JAK2 V617F positive and about 50 to 60% of 
patients with ET and PMF, thus the question has been proposed as to how patients, who are JAK2 
V617F negative, still display similar clinical features to those who have the mutation. This may suggest 
that they result from the deregulation of the same JAK/STAT pathway, activated by the occurrence of 
other gain of function mutations (35).  
1.2.2 Other Mutations 
The JAK2 V617F mutation is a gain of function mutation located in exon 14. However several gain of 
function JAK2 mutations have been discovered since, on exon 12 (36). They have been shown to 
cause hypersensitivity and activation of the erythropoietin receptor signalling pathways. These 
mutations on exon 12 were shown in studies to be characterized by isolated erythrocytosis at clinical 
onset in patients who are JAK2 V617F negative, and also to have a similar disease progression to 
patients who are JAK2 V617F positive (37). A prospective study on 338 patients diagnosed with PV 
revealed that 4.1% of these patients carried a JAK2 mutation on exon 12. 
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The MPL (Myeloproliferative Leukaemia Virus) oncogene encodes the Thrombopoeitin Receptor 
(TPO-R) protein. MPL is key in growth and survival of megakaryocytes. Gain of function MPL 
mutations have also been described that is associated with an MPN phenotype, and includes 
splenomegaly, thrombocytosis, myelofibrosis, and an increased risk of thrombosis (38). 
Subsequently, other MPL mutations including MPLW151L and MPLW151K were described in 
patients with ET and PMF at frequencies ranging from 3% to 15% (39).  
Another mutation that has been recently described is Calreticulin (CAL-R). CAL-R is an oncogene 
present in the endoplasmic reticulum, involved in ensuring proper glycoprotein folding, contributing 
to calcium homeostasis, and also influences processes such proliferation, apoptosis and immune 
responses (40). A CAL-R mutation was found in 70% to 84% of patients diagnosed with ET and PMF 
without JAK2 or MPL mutations (41). The significant number of patients with this mutation definitely 
warrants further research into a possible new diagnostic approach to MPN, as well as provides new 
insight into further therapeutic options. 
1.3 CLINICAL PRESENTATION 
Many patients have been diagnosed with a MPN after an incidental abnormal finding on full blood 
counts, having presented to their general practitioner with non-specific symptoms. However, there 
are patients that have presented with much more debilitating features such as thrombosis or 
haemorrhage. These features lead to significant morbidity and mortality amongst the afflicted 
patients. The symptomatic burden may be severe and also present in most patients with the disease. 
The signs and symptoms are a result of the disease process such as hyperviscosity in PV, 
thrombocytosis in ET, or extramedullary haemopoeisis in PMF. 
Non-specific symptoms such as fatigue, headaches, dyspnoea, blurred vision, night sweats, and 
abdominal discomfort have been reported in patients with a MPN. Hypermetabolic symptoms such as 
a low grade fever, weight loss, and night sweats have also been reported, especially in patients with 
PMF (42). A more common complaint in those with PV has been pruritus. Aquagenic pruritus which is 
severe epidermal itching evoked by contact of water, has been reported in 43% of patients in one 
study (43). Another symptom that causes distress to patients particularly with PV and ET is 
erythromelalgia. This is the burning sensation of hands and feet with associated erythema or cyanosis, 
and is deemed as pathognomonic of microvascular thrombotic complications (44). Both these 
symptoms seem to be fairly responsive to aspirin treatment. Altered blood viscosity leads to 
symptoms of epigastric distress as well as transient visual disturbances due to alterations in the gastric 
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and retinal blood flow. Patients with PMF also tend to complain of bone pain, as a result of 
osteosclerosis or periostitis. A prospective study on patients with MPN was able to formulate a 
Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF), which is able to gauge MPN 
severity and debilitation (45). 
Organomegaly in the form of splenomegaly and hepatomegaly are common in MPN due to the process 
of increased cell turnover as well as extramedullary haemopoeisis. Massive splenomegaly is the 
hallmark of PMF, and also carries the risk of splenic infarction (46). Pallor is the result of anaemia and 
other features such as petechiae, or purpura is secondary to bleeding from abnormal platelet function. 
The more serious and fatal complications are associated with thrombotic and haemorrhagic 
manifestations of disease. Thrombotic arterial and venous disease is a common presenting feature of 
MPNs, with increased rates seen in PV and ET. Risk factors for arterial thrombosis includes advanced 
age, previous thrombosis, a history of cardiovascular risk factors and JAK2 V617F positive disease (47). 
Studies also revealed that 23% of patients diagnosed with splanchnic vein thrombosis were further 
diagnosed with a MPN (48). The fact that all Ph1 negative MPN have the propensity to transform into 
each other, may make it difficult to classify initially, however they may also transform into an acute 
leukaemia. This could be part of the evolution of disease, however in a prospective study of 1683 
patients, it was noted that the use of cytoreductive agents in patients with PV showed an increased 
risk for transformation to acute myeloid leukaemia (49).  
The diagnosis of MPN is first suspected when abnormalities of the full blood count accompanies the 
clinical features mentioned. Laboratory features include an increase in haemoglobin (Hb), haematocrit 
(Hct), uric acid (UA) and lactate dehydrogenase (LDH) in patients with PV, however decreased levels 
of erythropoietin (EPO) are seen. A thrombocytosis in ET, and anaemia with a leucoerythroblastic 
picture on the blood film, is commonly reported in PMF. However, the diagnosis is always not obvious, 
and may require further investigations such as a bone marrow aspirate and trephine to assess for 
features such as fibrosis, other bone marrow infiltration, and to rule out possible chronic myeloid 
leukaemia (CML). Of importance is to rule out other reactive causes of thrombocytosis, or secondary 
causes of polycythaemia, before a diagnosis is made. The investigation of JAK2 V617F mutation by 
Polymerase Chain Reaction has been available to South Africa since 2005, and proves valuable in the 
diagnosis of MPN. 
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1.4 CLASSIFICATION 
Table 1: The 2008 World Health Organization diagnostic criteria for Polycythaemia 
Vera, Essential Thrombocythaemia, and Primary Myelofibrosis (2) 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
   
WHO indicates World Health Organization; PV, polycythaemia vera; ET, essential thrombocythaemia; 
PMF, primary myelofibrosis; Hgb, haemoglobin; CML, chronic myelogenous leukemia; MDS, 
myelodysplastic syndrome; BM, bone marrow; Epo, erythropoietin; LDH, lactate dehydrogenase; 
EEC, endogenous erythroid colony.  
*The diagnosis of PV requires meeting either both major criteria and 1 minor criterion or the first major 
criterion and 2 minor criteria. 
§The diagnosis of ET requires meeting all 4 major criteria. 
#The diagnosis of PMF requires meeting all 3 major criteria and 2 minor criteria. 
±Or Hgb or hematocrit greater than the 99th percentile of reference range for age, sex or altitude of 
residence or red cell mass > 25% above the mean normal predicted. 
¦small to large megakaryocytes with an aberrant nuclear/cytoplasmic ratio and hyperchromatic and 
irregularly folded nuclei and dense clustering. 
              PV* 
1 Hgb >18.5 g/dL   
(men)>16.5g/dl       
(women) or Hgb >17g/dL 
(men), or >15g/dL (women) 
if associated with a 
sustained increase of ≥ 
2g/dL from baseline that 
cannot be attributed to 
correction of iron deficiency 
or± 
 
2 Presence of JAK2V617F or 
similar  mutation 
 
 
        ET§ 
1 Platelet count ≥450 × 10⁹/L 
2 Megakaryocyte 
proliferation with large and 
mature morphology. No or 
little granulocyte or 
erythroid proliferation. 
3 Not meeting WHO criteria 
for CML, PV, PMF, MDS or 
other myeloid neoplasm. 
4 Demonstration of 
JAK2V67F or other clonal 
marker or no evidence of 
reactive thrombocytosis.  
 
 
 
 
        PMF# 
1 Megakaryocyte proliferation 
and atypia¦ accompanied by 
either reticulin and/or 
collagen fibrosis, or in the 
absence of reticulin fibrosis, 
the megakaryocyte changes 
must be accompanied by 
increased bone marrow 
cellularity, granulocytic 
proliferation and often 
decreased erythropoiesis (ie 
prefibrotic PMF). 
2 Not meeting WHO criteria for 
CML, PV, MDS or other 
myeloid neoplasm. 
3 Demonstration of JAK2V617F 
or other marker or no 
evidence of reactive bone 
marrow fibrosis. 
Major criteria 
1 BM trilineage myleoproliferation   
2 Subnormal serum Epo level 
3 EEC growth  
1 Leukoerythroblastosis 
2 Increased serum LDH 
3 Anemia  
4 Palpable splenomegaly 
Minor criteria 
 
 
.4   CLASSIFICATION 
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In 1967 Louis Wasserman assembled a group of investigators and founded the Polycythaemia Vera 
Study Group (50). They were grouped in order to study PV, establish diagnostic criteria, and also to 
conduct further clinical trials. In 2001 the WHO published new criteria for MPN, which addressed 
certain deficiencies in previous ones, such as the emphasis on bone marrow findings (51). Since the 
discovery of JAK2 and MPL mutations, a further revision has been made to the criteria for MPN in the 
2008 WHO publication (2).  
The diagnosis for PV includes 2 major criteria i.e. an increased haemoglobin level and the presence of 
JAK2 V617F or similar mutation, and 3 minor criteria i.e. trilineage myeloproliferation on bone marrow 
investigation, a subnormal serum EPO, and the growth of endogenous erythroid colonies in the 
absence of EPO. Either both major criteria or 2 minor criteria is sufficient to make a diagnosis of PV, 
or even 1 minor criteria and the first major criteria (2). 
An ET diagnosis requires 4 major criteria which consists of a platelet count of ≥ 450 x 10⁹/L, a 
megakaryocyte proliferation with large and mature morphology, a JAK2 V617F or similar mutation, 
and not meeting criteria for PV, PMF, CML, or other myeloid neoplasm (2). Bone marrow features of 
fibrosis or increased cellularity, the presence of clonal markers, as well as features of 
leukoerythroblastosis, anaemia, palpable splenomegaly and a raised LDH, are all criteria required for 
a diagnosis of PMF (2).  
With an ever growing knowledge of the Ph1 negative MPNs with regard to future cytogenetic and 
molecular discoveries, there will certainly be a new revision of the WHO 2008 criteria. Currently 
though it seems that bone marrow histology plays an integral part in making a distinction between 
reactive and clonal myeloproliferation (52).  
1.5 EPIDEMIOLOGY 
There is a paucity of epidemiological data on MPN. A recent study in the United States of America 
utilized two major United States health insurance claims databases to estimate the prevalence of MPN 
from 2008 to 2010. The study findings concluded that the prevalence of PMF ranged from 3,6 to 5,7 
per 100 000 patients, PV prevalence ranged from 45 to 57 per 100 000 patients, and ET prevalence 
was 39 to 57 cases per 100 000 patients (53). Another retrospective review of 2 112 patients in South 
East England showed incidences of 1,08 per 100 000 patients, 0,37 per 100 000 patients, and 1,65 per 
100 000 patients, for PV, PMF and ET respectively (54). Other studies done comparing data across 
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Europe revealed a wide variation in the prevalence and incidence of MPN and again confirmed the 
importance of better epidemiological data needed to assess the burden of illness (55). 
The number cases as well as the age specific incidence is also shown to increase with age, and 
incidences were in all ages seen to be higher for females than for males (56). Of interest is a study 
published in 1992, where epidemiological parameters were noted in a group of people in northern 
Israel. This study revealed a 10 to 20 fold higher incidence of MPN in Ashkenazi Jews compared to the 
Arab population, and emphasises the importance of genetic predisposition possibly interacting with 
acquired factors in the pathogenesis of the disease (57). Demographic data for Africa is severely 
lacking and further research needs to be carried out to compare the burden of MPN with the rest of 
the world. 
1.6 MANAGEMENT OF MPN 
The treatment of MPN has evolved over the past years, especially since the discovery of the JAK2 
V617F mutation. Newer and hopefully more effective treatment is being researched and many trials 
are still ongoing. Due to the heterogeneous nature of the disease, the timing of treatment and which 
agents to use, has been difficult in the management process. As stated before, MPN have a significant 
burden of disease symptoms and a heightened risk for thrombotic and haemorrhagic complications. 
There has also been no therapy discovered that has led to cure of the disease, except for allogeneic 
stem cell transplantation. Therefore, it is seen historically that the aim of treatment was concentrated 
on alleviating symptoms of disease and preventing debilitating complications. 
 
In 2011, a panel of experts were convened by the European Leukemia Network (ELN) to produce an 
evidence based algorithm for the treatment of MPN (58). Factors addressed by this group included 
the correct time to initiate treatment as well as a recommendation of agents to be used. Life 
expectancy of ET and PV may not be diminished but patients diagnosed with PMF unfortunately do 
not fare as well. It is for this reason that the goals of treatment for PV and ET were similar and those 
for PMF would be more individualized. The primary goals of therapy for PV and ET are to prevent the 
complications of thrombosis and bleeding, as well as halting the progression to myelofibrosis and 
acute myeloid leukaemia, and finally to control disease related symptoms (59). In contrast, the goals 
for PMF is to alleviate symptoms caused by factors such as cytopaenias and splenomegaly, as well as 
workup for possible allogenic stem cell transplant (Allo-SCT).  
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According to the treatment recommendations proposed by the ELN, before initiating therapy in a 
patient who has been diagnosed with a MPN, the prognosis as well the symptomatic burden should 
be assessed (60). The Myeloproliferative Neoplasm Symptom Assessment Form total symptom score 
(MPN-SAF TSS) is a scoring system that utilizes 10 symptoms of disease and is shown to accurately 
assess symptom burden (60). This can also be used to assess symptomatic response after treatment 
has been initiated. The prognostic assessment of MPN can be achieved by commonly used scoring 
systems. These scores have been validated in predicting survival and risk of thrombosis. Tefferi et al 
developed a model for assessment of prognosis for PV, which is still commonly used (61). The 
International Prognostic Score for ET (IPSET) is a model developed to assess prognosis of WHO defined 
ET (62). PMF prognostic assessment can be estimated using the International Prognostic Scoring 
System (IPSS) at the time of diagnosis, while the Dynamic International Prognostic Scoring System 
(DIPSS) is used at any time during the disease process (63). Patients are thus put into a high risk or low 
risk category for prognosis and a plan of therapy can then take place. 
 
After stratification of risk and MPN symptom burden, the treatment for PV and ET follow a similar 
course. Conventional therapy such as allopurinol to prevent secondary gout, as well as aspirin to 
reduce the risk of vascular events, may be initiated. Phlebotomy in patients with PV has been shown 
to also to reduce risks of thrombotic and cardiovascular events, when the haematocrit has been 
reduced to below 45% (64). Cytoreductive therapy would have to be initiated for patients with high 
risk profiles. Agents such as hydroxyurea (HU), anagrelide, interferon alpha (IFN), or busulphan (BU) 
may be used as single therapy or as combination therapy, although some may use these with caution 
due to their leukaemogenic risk. Clinical trials involving JAK2 inhibitors are also underway and results 
regarding their efficacy in PV and ET patients are eagerly awaited. Management of PMF is guided by 
symptomatology, and treatment such as corticosteroids, androgens, immunomodulatory agents (e.g. 
thalidomide), and splenectomy have been used for symptomatic anaemia (65). Blood and platelet 
transfusions should be given where necessary as well, but ideally high risk patients should be worked 
up for Allo-SCT and also be initiated on Ruxolitinib which has shown success on its effects on symptoms 
and splenomegaly (66). 
 
JAK inhibitors have shown promise for PMF and the other trials for alternative therapy is also 
underway. These will try to ascertain whether targeting other pathways by using agents such as 
histone deacetylase (HDAC) inhibitors will help us further in the future. Unfortunately, agents such as 
the JAK inhibitors are not freely available in the state hospitals in South Africa and thus effective and 
more modern approaches to management is limited. 
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1.6.1 ASPIRIN 
Aspirin is a salicylate drug that is also referred to as acetylsalicylic acid. Its main use is for its analgesic, 
antipyretic, and anti-inflammatory properties. Due to the fact that it inhibits the production of 
thromboxane, thus has antiplatelet effects, it is used in low doses for prevention of cardiovascular 
disease. It has thus also been assessed for the prevention of vascular events in PV and ET. The ECLAP 
study demonstrated that low dose aspirin can safely prevent thrombotic complications in patients 
with PV, who don’t have contraindications to it (67). The role of aspirin in ET is less clear. It remains 
one the main frontline therapies for PV and ET patients (65). Side effects include gastrointestinal 
ulcers, risk of bleeding in patients who are predisposed, and Reyes syndrome in children. 
1.6.2 PHLEBOTOMY 
   
Phlebotomy, also known as bloodletting or venesection, has been part of medical therapy for around 
3000 years. In the time of Hippocrates, around 460 BC, the removal of blood when one was ill was 
common practice. It was practiced in the past by using lancets, cupping, or even the use of leeches 
(68). The use of therapeutic phlebotomy is currently indicated for 3 disease processes: 
haemochromatosis, porphyria cutanea tada, and PV. One of the characteristics of PV is an increased 
red cell mass and thus a raised calculated haematocrit (Hct). Many studies were done over the years 
that proved that thrombotic events were related to the increased Hct level and therefore reducing 
the Hct would lead to preventing this complication (68). No consensus has been reached regarding 
the target Hct level, but a large trial in Italy called the CYTO-PV trial, revealed that Hct levels in patients 
with PV that were below 45% had a particularly lower rate of thrombosis and cardiovascular death 
(69). Other trials showed using combination therapy including HU, 32 Phosphorus (32P), and aspirin, 
also helped cement the importance of therapeutic phlebotomy in PV (68).  
     
Agents such as HU or anagrelide may be used as an alternative, if the patient is intolerant to 
venesection. Complications of venesection may include tiredness or vasovagal responses, and iron 
deficiency may develop which should be supplemented for, when the patient becomes symptomatic 
(70). Of importance also, is to optimize other cardiovascular risk factors such as diabetes mellitus and 
hypertension, so as to further decrease the risk of thrombosis. The frequency of venesection is 
determined by the level of the Hct and therefore adequate monitoring is imperative.     
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1.6.3 HYDROXYUREA 
Hydroxyurea is an antineoplastic agent that is also known as hydroxycarbamide. It acts by inhibiting 
the enzyme ribonucleotide reductase, therefore reducing the production of deoxyribonucleotides, 
which are important in DNA synthesis. This drug is used for its cytoreductive action, and therefore its 
use has been indicated for MPN such as PV, ET, and CML. Fetal haemoglobin concentration is also 
increased and thus hydroxyurea has been effective in the prevention of painful crises in sickle cell 
anaemia (71). It is administered orally and reaches peak plasma levels within 4 hours.  
Many clinical trials over the years have proven the effective nature of hydroxyurea in MPN, due to its 
myelosuppressive actions. Cortelazzo et al demonstrated in their study of 114 patients with ET that 
hydroxyurea is effective in the prevention of thrombotic episodes (72). ELN has also now 
recommended that hydroxyurea be the first line cytoreductive agent for patients with high risk MPN 
(65). Other uses in MPN has been the reduction in spleen size in patients with PMF presenting with 
symptomatic splenomegaly (73). 
All drugs have their pros and cons, and hydroxyurea is no different. Therefore, careful monitoring of 
the full blood count is necessary due to the suppressive nature of hydroxyurea on the bone marrow. 
Another concern for haematologists and oncologists has been the possible risk of leukaemogenesis. 
There is no definite evidence of this claim when hydroxyurea is administered as a single agent, 
however its use may increase the leukaemic potential of other cytoreductive drugs (74). 
1.6.4 ANAGRELIDE 
Anagrelide is a platelet lowering agent belonging to the class of phosphodiesterase inhibitor drugs. It 
is used in the treatment of thrombocytosis in patients with ET and is also recommended as second 
line therapy by ELN, in patients who are intolerant to hydroxyurea (65). Several studies have 
demonstrated its efficacy in lowering platelet counts in patients with ET, however there was also an 
increased incidence of marrow fibrosis associated with its use (75). The incidence of arterial and 
venous thrombosis was higher than hydroxyurea in clinical trials of patients with ET, where anagrelide 
was compared to hydroxyurea (75). Therefore, one can conclude that hydroxyurea may be superior 
to anagrelide in treatment of ET. The ANAHYDRET study however revealed that there was no 
significant difference between the two drugs with regard to thrombotic complications of ET (76). It 
still remains in the context of ET treatment, as a 2nd line therapy.  
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1.6.5 BUSULPHAN 
Busulphan is an alkylating agent that has been utilised for many years in the treatment of patients 
with MPN. It acts by inducing cross linkages between DNA bases thereby preventing DNA replication. 
Other indications include bone marrow conditioning for patients undergoing bone marrow 
transplantation. Metabolism of the drug occurs in the liver. Therefore many drug interactions may 
result which have an effect on its metabolism. There has been caution regarding its use due to 
complications of severe cytopenias, pulmonary fibrosis, and possible leukaemogenicity, as reported 
in previous trials (49). When patients with PV become intolerant to phlebotomy or hydroxyurea, the 
options of further treatment is fairly limited. A study by Alvarez-Larran et al assessed busulphan in 36 
patients with PV and ET who were refractory or intolerant to hydroxyurea (77). This study revealed 
that it is effective as a 2nd line option in elderly patients with ET or PV intolerant to hydroxyurea, but 
there was still a concerning risk of disease transformation (78).   
1.6.6 INTERFERON  
Interferons are a group of glycoproteins that are produced in cells in response to various stimuli, 
including viral, protozoal, and bacterial infections or by tumour cells. It was discovered in 1957 by 
Lindeman and Isaacs, who described it as a substance that could cause viral interference (78). Over 
the next few years research has been ongoing regarding its therapeutic effects in malignant disease. 
It has been recently classified into 2 groups by virtue of their ability  to bind to common receptor types 
i.e. Type 1 and Type 2 (79). Interferon alpha, beta, omega, and tao belong to the Type 1 group, while 
interferon gamma belongs to the type 2 group. Functions include immunomodulatory, antiviral, and 
antitumor activity. The production of interferon by recombinant rDNA technology has allowed for 
research to be done regarding its efficacy against tumour cells. Interferon alpha has been used in the 
treatment of MPN, particularly CML, because of its ability to inhibit myeloproliferation and thus cause 
clinical and haematological reduction in disease. In a study of 279 patients revealed that interferon 
alpha was an effective alternative to the 1st line treatment in PV (80). Newer preparations 
manufactured by adding polyethylene glycol to the interferon, prolongs the action of the agent, and 
is called pegylated interferon. A phase 2 trial of 79 patients with either ET or PV also demonstrated 
complete response rates of 76% and 70% respectively, with the use of pegylated interferon alpha 2a 
(81). A further trial assessing the efficacy and safety of pegylated interferon alpha 2a against 
hydroxyurea in PV and ET patients is underway (65). The intolerability of the drug may be its downfall, 
with hepatic and neurological side effects, as well as ‘’flu-like’’ symptoms such as fever and malaise. 
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1.6.7  PHOSPHORUS-32 
Phosphorus-32 (32P) is a synthetic radionuclide that has been used in the treatment of haematological 
malignancies for many years. The localization of the radioisotope in leukaemic cells, as well as the 
liver, bone, and spleen was demonstrated by John Lawrence in 1939, and this was enough to suggest 
that it would have a future therapeutic role (82). It then became the agent used to treat chronic 
leukaemia as well as PV and ET. The use of 32P has been studied extensively, especially for its 
outcomes in PV and ET. In a prospective study of 431 patients in 1981, where many treatment 
modalities were used in patients with PV and ET, it was recommended that 32P be used in patients 
greater than 70 years of age (83). Currently, its use has been less favoured and newer treatments are 
used. The leukaemogenic potential of this agent and the difficulty in obtaining it has led to the 
reduction in its use and it currently is not a recommended treatment option (82). 
 
1.6.8 DANAZOL 
Danazol is a derivative of the synthetic steroid ethisterone. The luteinizing hormone increase in the 
middle of the menstrual cycle is suppressed by this agent, and thus it prevents ovulation. It is used in 
the treatment of endometriosis. Masculinization of patients, as well as hepatotoxicity, are some of 
the well- known side effects of extended use of this agent. Studies over the years have demonstrated 
its advantageous role in the treatment of patients with autoimmune haemolytic anaemia and immune 
thrombocytopenia (84) (85). It has also been used in the treatment of MPNs, particularly in the 
treatment of anaemia in patients with PMF (86). In a study of 30 patients diagnosed with PMF by 
Francisco Cervantes et al, danazol was used for the treatment of anaemia in these patients, with 37% 
showing a complete response (87). Another study of 18 elderly patients refractory to conventional 
therapy, demonstrated that the concurrent use of danazol with chemotherapy improved the quality 
of life in these patients (88). The beneficial role of danazol in patients with MPN with refractory 
pruritus was shown in a small study of 22 patients (89).  
 
1.6.9 JAK INHIBITORS AND OTHER NEW THERAPIES 
JAK inhibitors are newly discovered agents that modulate immune response in MPN and other disease 
states, by inhibiting one of the Janus Kinases and thus depressing the effect of the JAK-STAT pathway. 
Following the success of the tyrosine kinase inhibitor Imatinib for the treatment of CML, the discovery 
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of the JAK inhibitors in 2011 was hopefully the answer for Ph1 negative MPN. This has led to multiple 
trials in the recent past as well as currently, in the hope that a possible cure could be imminent for 
this disease process. Its uses may prove beneficial not only for MPN, but for other diseases such as 
rheumatoid arthritis and psoriasis (90) (91).  
 
The improvement of symptoms, reduction in splenomegaly, and prolongation of life, are major factors 
that a new agent should aim to achieve in the treatment of MPN. The approval of use of Ruxolitinib 
by the U.S. Food and Drug Administration (FDA) for its use in PMF, was due to two important trials 
displaying successful administration of this JAK2 inhibitor (92). Ruxolitinib is an inhibitor of both JAK1 
and JAK2 and has thus been studied extensively. The COMFORT 1 trial, where patients with 
intermediate or high risk myelofibrosis were given twice daily doses of ruxolitinib or placebo, revealed 
that the agent was effective in treatment of myelofibrosis (93). Reductions in the size of splenomegaly 
as well as improved survival and symptomatology were successfully demonstrated in this trial (93). 
The COMFORT 2 trial randomised 219 patients with myelofibrosis to Ruxolitinib or the Best Available 
Treatment (BAT), and this also demonstrated upto a 50% reduction in spleen size, as well as a 
probability of survival of 71% of patients after a 3,5 year follow up analysis (94). There are ongoing 
trials studying the effects of Ruxolitinib in patients with PV and ET (95). Side effects of Ruxolitinib 
include cytopenias, gastrointestinal upset, as well as bruising. 
 
Other JAK inhibitors still undergoing trials include agents such as Momelotinib, Fedratinib, and 
Pacritinib, and we await their approval in the near future (96) (97). The potential for symptom 
reduction and overall better survival is promising but to date there is no data showing molecular or 
cytogenetic reversals (92). The fact that MPNs are a result of abnormal JAK-STAT pathway signalling, 
and that no obvious cure is currently available, this has led to other treatment targets being explored. 
Other pathways or molecules that influence cellular growth, differentiation, and apoptosis are being 
targeted in newer trials that are now underway. PI3 pathway inhibitors as well as mTOR inhibitors are 
being studied in combination with JAK inhibitors, hoping that another alternate approach can be 
demonstrated (98) (99). Another agent being studied is Ginovostat, a Histone Deacytelase Inhibitor, 
and in combination with Ruxolitinib, will hopefully show successful results in the treatment of MPN 
(100).  
 
The discovery of the JAK inhibitors has certainly created excitement in the therapeutic approach to 
Ph1 negative MPN. First world countries are leading the way in the discovery of many new agents and 
thus new evolving treatment strategies are being studied. Although the private hospital institutions in 
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South Africa can acquire these new agents, the state sector is almost always reliant on conventional 
therapies. 
1.6.10 ALLOGENEIC STEM CELL TRANSPLANTATION (Allo SCT) 
Allo SCT is the process where haematopoietic stem cells are transplanted from a donor to a recipient. 
Donors must have a tissue Human Leucocyte Antigen (HLA) type that matches the recipient, and 
donors may be related to the recipient e.g. siblings, or they may be unrelated. The introduction of 
stem cell transplantation to the medical world was by E. Donnall Thomas in the 1950’s (101). This led 
the way to future stem cell transplantations, especially in the treatment of leukaemias, lymphomas, 
as well as non-malignant haematological disease such as thalassemia and aplastic anaemia. Another 
type of stem transplantation is autologous stem cell transplantation (Auto SCT), which involves 
transplantation of stem cells, into a recipient, that has been extracted and harvested from the same 
person. The benefit of Auto SCT involve reductions in the post-transplant complications such as 
infections as well as graft-versus-host-disease, although an increase rate of disease relapse, especially 
in diseases like leukaemia have led to Allo SCT being favoured in certain circumstances. 
 
The process also includes the conditioning of the bone marrow, and a myeloablative or a non-
myeloablative approach can be used (102). Complications include infections, graft-versus-host-
disease, veno-occlusive disease, and mucositis, which leads to increased incidence of morbidity and 
mortality. The use of Allo SCT may be the only cure for the Ph1 chromosome negative MPN, PMF. Allo 
SCT should be considered for intermediate to high risk patients diagnosed with PMF, where a survival 
of less than 5 years is expected (58). It would therefore be imperative, that after diagnosis and risk 
stratification of PMF, the physician should assess the candidacy for Allo SCT. Few studies have been 
done to demonstrate the success of Allo SCT in patients with PMF or post PV or Post ET myelofibrosis, 
and one of these studies showed a longer term relapse free survival (103). Other studies compared 
the use of reduced intensity conditioning before Allo SCT in patients with myelofibrosis, and this 
proved to be superior to the old myelo-ablative approach, with regard to increased survival (104) 
(105). More trials of stem cell transplantation use in the treatment of MPN is needed to further 
understand and perfect the process, and better the chances for a definite cure. 
 
The emerging importance of stem cell transplantation worldwide has also led to multiple willing 
donors globally, and the formation of bone marrow registries. Locally, the South African Bone Marrow 
Registry (SAMBR) was established in Cape Town in 1991 (106). This offers South Africa the option of 
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Allo SCT for a variety of conditions. There is no doubt that Allo SCT has become an important mode of 
treatment for haematological disease, locally as well as internationally (107). 
1.7 OUTCOMES 
 
Several studies were conducted worldwide assessing patterns of survival in Ph1 negative MPN. The 
results of these demonstrate that patients with PV and ET have a good prognosis, with a slight 
reduction in overall survival compared to the general population (108). Also revealed was the fact that 
PMF had an inferior survival compared to ET and PV (108). The major causes of mortality and morbidity 
include thrombosis, haemorrhage and clonal evolution. In a large study called the European 
Collaboration on Low Dose Aspirin in PV (ECLAP), 41% of deaths were due to cardiovascular mortality 
(109). Leukaemic transformation carries a very poor prognosis for patients with MPN, even though 
they occur at low rates (110). Treatments of MPN are thus targeted at reducing these sometimes fatal 
complications of the disease. 
 
Different scoring systems have been developed to assess prognosis in patients with MPN, such as the 
IPSET score for ET and the IPSS and DIPSS scores for PMF (111). This assists in risk stratifying patients 
and therefore creating an appropriate management plan. Factors that were universally shown to have 
caused significant morbidity and mortality were an increasing age of greater than 65 years, increased 
red cell and platelet counts, and a previous history of thrombosis (111). Criteria to define the 
outcomes or response to therapy for MPN have been revised and standardised by ELN and the 
International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) 
(112) (113). No cure is yet available and thus a high index of suspicion and risk stratification is needed 
to try and alleviate some of the fatal complications of the disease and further improve survival rates. 
1.8 CONCLUSION 
Philadelphia chromosome negative myeloproliferative neoplasms are a rare haematological disease 
that has the ability to cause major morbidity and mortality. The better understanding of its 
pathogenesis especially in regard to the several mutations it exhibits, will hopefully lead to more 
effective therapy, and create better outcomes in the future. 
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1.9 OBJECTIVES OF THE STUDY 
 To assess the demographics; clinical presentation; complications; and management of MPN 
 To describe the prevalence of JAK2 V617F mutation in MPN 
 To describe the treatment modalities that were available and used to treat patients with MPN 
 To assess the outcome of different treatment modalities used to treat patients with MPN 
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CHAPTER 2: PATIENTS AND METHODS 
2.1 STUDY DESIGN 
A retrospective review of adult patients seen at the Clinical Haematology Unit, Department of Internal 
Medicine, Chris Hani Baragwanath Academic Hospital from the period 01/01/1987 to 31/12/2011. 
 
2.2 SAMPLE POPULATION 
There were a total of 116 patients identified in the sample population at the Clinical Haematology 
Unit, however, only 94 patients had records with sufficient information that were used in the study. 
 
2.2.1 INCLUSION CRITERIA 
 All patients ≥ 18 years of age 
 All patients diagnosed specifically with PV, ET, and PMF 
 
2.2.2 EXCLUSION CRITERIA 
 Patients diagnosed with CML 
 Patients diagnosed with other MPN (e.g. systemic mastocytosis, chronic neutrophillic 
leukaemia, chronic eosinophilic leukaemia, hypereosinophilic syndrome, and MPN 
unclassifiable) 
 Patients whose records were inadequate and insufficient for data analysis  
 
2.3 COLLECTION OF DATA 
Data was collected retrospectively from patients diagnosed with MPN, excluding CML, for the period 
01/01/1987 to 31/12/2011 (25 years). Permission was obtained from the Head of the Clinical 
Haematology Unit, as well as the Head of the Department of Internal Medicine, to perform the study. 
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A standardised data sheet which included a tick box list for documentation of the data was used 
(Appendix A and B). 
The following information was obtained: 
 Demographics: age and gender 
 Clinical presentation based on documented history and examination 
 Laboratory investigations including full blood counts, urea and electrolytes, haematinics, uric 
acid, and bone marrow characteristics 
 Blood results were recorded for different periods in time i.e. at time of presentation, at time 
of best response to treatment, and at time of the patients last follow up visit or at the time of 
death 
 JAK2 V617F mutation was detected by polymerase chain reaction testing and was obtained 
from the patient records 
 Management including venesection, blood transfusions, medication, number of treatments, 
and duration of treatment, was obtained from the haematology files 
 Information regarding the complications of MPN including arterial and venous thrombosis, 
bleeding and leukaemic transformation were obtained from the haematology files 
 Outcomes for ET were defined as follows: 
o Complete response is defined as a platelet count ≤ 400 x 10 ⁹/L, and no disease 
related symptoms, and a normal spleen size on imaging, and white blood cell count 
≤ 10 x 10⁹/L (114). 
o Partial response is defined as patients who do not fulfil the criteria for complete 
response, platelet count ≤ 600 x 10⁹/L or a decrease > 50% from baseline (114). 
o Stable disease is defined as a response that does not satisfy complete or partial 
response 
o Death as a consequence of ET 
 Outcomes for PV were defined as follows: 
o Complete response is defined as a haematocrit < 45% without phlebotomy, and 
platelet count ≤ 400 x 10⁹/L, and white cell count ≤ 10 x 10⁹/L, and normal spleen size 
on imaging, and no disease related symptoms (114) 
o Partial response is defined as patients who do not fulfil the criteria for complete 
response, haematocrit < 45% without phlebotomy, or response in 3 or more of the 
other criteria (114) 
o Stable disease is defined as a response that does not satisfy complete or partial 
response 
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o Death as a consequence of PV 
 
 Outcome of PMF is defined as follows: 
o Complete response is defined as haemoglobin ≥ 10 g/dl and < the upper limit of 
normal limit, neutrophil count ≥ 1 x 10⁹/L and < upper normal limit, and a platelet 
count ≥ 100 x 10⁹/L, and a resolution of disease symptoms with no palpable liver and 
spleen, and bone marrow normocellularity with < 5% blasts and ≤ grade 1 
myelofibrosis (113) 
o Partial response is defined as resolution of disease symptoms with no palpable liver 
or spleen, and either bone marrow features as above, or peripheral blood features as 
above (113) 
o Stable disease is defined as a response that does not satisfy criteria for complete or 
partial response 
o Death as a consequence of PMF  
Patients’ names and details were recorded and kept confidentially. A numerical coding system was 
used to ensure confidentiality. The REDCap research database was used to capture the information 
from the data collection sheet. REDCap is a research database that allows for the electronic capture 
of data by utilising a created electronic data collection sheet. It then also allows for the exportation of 
the information to a statistical program. It is a secure web based program that is accessed via the 
internet, and it is protected by a password for which the researcher uses to gain access. 
 
 2.4 DATA ANALYSIS 
Once the data was collected, it was verified using the software provided by the REDCap program. The 
verified data was then exported to Microsoft Excel for further analysis. Microsoft Excel was then used 
for statistical analysis. Descriptive analysis in the form of mean and median was used for demographic 
statistics as well as blood results, using standard deviations or range for continuous variables. Mean 
and standard deviations were used for parametric data while median and interquartile ranges were 
used for non-parametric data. Categorical data was illustrated using frequency distribution tables, pie 
charts and bar charts. Further statistical analysis was shown by using graph pad instat. 
 
Bivariate and multivariate analysis of categorical data was done by using contingency tables. Paired, 
parametric data was analysed using the paired t-test, while unpaired, non-parametric data was 
analysed using the Kruskal-Wallis test. Survival curves for non-parametric data was created using the 
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log-rank test (Mantel-Cox test). A p value of < 0.05 determined statistical significance. A statistician 
was consulted to assist and verify the methods used. 
2.5 ETHICS 
Ethics approval was granted unconditionally by the Human Research Ethics Committee (HREC) of the 
University of the Witwatersrand (Clearance Certificate Number: M121175). Informed consent was not 
needed from the patients due to the analysis being retrospective in nature.   
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CHAPTER 3: RESULTS 
3.1 DEMOGRAPHICS OF PATIENTS WITH MPN 
Table 2: Demographics of patients with MPN 
 
A total of 94 records were obtained and reviewed from the Clinical Haematology Unit, 
Department of Internal Medicine, at Chris Hani Baragwanath Academic Hospital. These 
patient records were analysed in the 25 year period, from 1 January 1987 to the 31 December 
2011. 
Of the 94 records analysed 42 (45%) were diagnosed with PMF, 35 (37%) were diagnosed with 
ET, and the least amount 17 (18%) of patients were diagnosed with PV. The median age of 
patients diagnosed with MPN was 61.5 years with a mean age of 59.5. A younger median age 
of 54 years was identified in the PV group, while median ages of 63 and 63.5 were noted in 
the ET and PMF groups respectively. 
 All Patients  ET PV  PMF  
NUMBER 94 35  17  42  
     
AGE (years) (mean ± SD) 59,5 ± 14.4 58,4±16,5 52,8±12,2 63,2±12,2 
AGE (years) (median ± IGR) 61,5 (21 -87) 63 (21 – 80) 54 (32 -78) 63,5 (39 – 87) 
     
GENDER - MALE 42 (45%) 11 (31%) 10 (59%) 21 (50%) 
                 FEMALE 52 (55%) 24 (69%) 7 (41%) 21 (50%) 
     
M:F RATIO         1: 1.24 1: 2.2 1: 0.7 1: 1 
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As illustrated in figure 1, there is a slight female predominance (1.24:1) of all patients 
diagnosed with a MPN, with 55% of patients identified as female and 45% identified as male. 
A female predominance was shown in ET, while a male predominance was noted in PV and 
an equal gender ratio in PMF (see figures 2, 3, and 4).      
 
Figure 1: Gender distribution in MPN 
 
Figure 2: Gender distribution in ET 
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Figure 3: Gender distribution in PV 
 
 
 
Figure 4: Gender distribution in PMF 
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3.2 PRESENTING SYMPTOMS IN PATIENTS DIAGNOSED WITH MPN 
 
Figure 5: Frequency of symptoms of all patients at presentation 
(Symptoms experienced in the ‘’Other’’ category were abdominal pain and deafness) 
 
 
Figure 5 illustrates multiple presenting symptoms of all 94 patients that were diagnosed with MPN. It 
is appreciated that the most common complaint in these patients was fatigue (85% i.e. 80 out of 94 
patients), and as demonstrated in figures 6, 7 and 8, fatigue was also shown to be the most common 
complaint in ET (80%), PV (88%), and PMF (82%) respectively. Other common symptoms experienced 
in all patients were weight loss (58%), night sweats (26%), and pruritus (25%). Bleeding (epistaxis and 
gum bleeding) was much more common in patients diagnosed with ET and PMF than in patients with 
PV (see figures 6, 7, 8). Of interest is that patients diagnosed with PV had significantly more complaints 
of pruritus (59%). Figure 8 demonstrates that a significant amount of patients with PMF presented 
with weight loss (82%).  Other symptoms that were shown during analysis included bone pain (20%), 
fever (17%), swelling or pain of the legs (9%), headaches (7%), dyspnoea (7%), and chest pain (5%), as 
seen in figure 5. Only 1 patient diagnosed with a MPN complained of erythromelalgia, while 3 patients 
with PMF experienced erectile dysfunction. 
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Figure 6: Frequency of symptoms in patients with ET 
 
 
Figure7: Frequency of symptoms in patients with PV 
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Figure 8: Frequency of symptoms in patients with PMF 
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3.3 CLINICAL PRESENTATION 
 
Figure 9: Frequency of clinical features found on examination 
 
Figure 9 illustrates the clinical features that were present on examination of these patients when they 
were referred to the Clinical Haematology Unit. Organomegaly on abdominal examination was shown 
to be the most common clinical feature, with splenomegaly occurring in 80% of all patients examined 
whilst hepatomegaly occurred in 53% of patients. The simultaneous occurrence of hepatomegaly and 
splenomegaly was demonstrated in 53% of the patients at presentation. Other features seen on 
examination include pallor (43%), fundal changes (13%), lymphadenopathy (12%), venous thrombosis 
(3%), and evidence of bleeding into the skin (12%).  
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Figure 10: Frequency of clinical features on examination in patients with ET 
Splenomegaly was the most common clinical feature in ET (60%). Other significant features were 
hepatomegaly (43%) and pallor (23%) (see figure 10). Patients with PV also had a splenomegaly in 76% 
of the records analysed, as seen in figure 11. The frequency of clinical features in PMF is illustrated in 
figure 12, with some striking data observed. Ninety seven percent of patients diagnosed with PMF had 
a splenomegaly while 71% had hepatomegaly on examination. Of note was that pallor was visible in 
78% of PMF patients on presentation. Only 6 patients were recorded as having any form of bleeding 
into the skin. Two patients diagnosed with ET presented with splanchnic vein thrombosis, and only 
one patient with PV presented with deep vein thrombosis. 
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Figure 11: Frequency of clinical features at presentation in patients with PV 
 
 
Figure 12: Frequency of clinical features at presentation in patients with PMF 
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3.3.1 HEPATOMEGALY IN PATIENTS WITH Ph1 NEGATIVE MPN 
Table 3: Comparison of Hepatomegaly in Ph1 Negative MPN 
Hepatomegaly 
All patients 
(n = 94) 
ET 
 (n = 35) 
PV 
(n = 17) 
PMF 
(n = 42) 
     
Number 50 (53%) 15 (42%) 5 (29%) 30(71%) 
     
Size below costal margin (in cm) 
(median±IQR) * 4(2-13) 3(2-10) 3(2-4) 5(2-13) 
 
*p value = 0,0381 (using Kruskal-Wallis test) 
 
Table 3 demonstrates a comparison between the 3 diseases (ET, PV, and PMF) regarding the number 
of patients presenting with hepatomegaly, as well as the size of the liver palpable below the right 
costal margin in the midclavicular line. Fifty three percent of all patients presented with a 
hepatomegaly at presentation. It is noted that patients with PMF were most likely to present with 
hepatomegaly (71%), and patients with PV were least likely to have a hepatomegaly (29%). The 
findings with regard to hepatomegaly were statistically significantly different in the 3 different MPN. 
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3.3.2 SPLENOMEGALY IN PATIENTS WITH Ph1 NEGATIVE MPN 
Table 4: Comparison of Splenomegaly in Ph1 Negative MPN 
Splenomegaly 
All patients 
(n = 94) 
ET 
(n = 35) 
PV 
(n = 17) 
PMF 
(n = 42) 
     
Number 75 (80%) 21(60%) 13 (76%) 41(98%) 
     
Size below costal margin  
(in cm) (median±IQR) * 4(1-28) 3(1-16) 2(1-8) 7(2-28) 
 
*p value = 0,001 (ANOVA using Kruskal-Wallis) 
ET vs PV  p value  > 0,05; ET vs PMF  p value < 0,01; PV vs PMF p value < 0,01 
 
A comparison of the median size of splenomegaly as well the number of patients presenting with 
splenomegaly is shown in Table 4. Eighty percent of all patients presented with a splenomegaly. Ninety 
eight percent of patients diagnosed with PMF had a splenomegaly. In the other 2 diseases, 21 of the 
35 patients diagnosed with ET (60%) had splenomegaly and 76% of PV patients had splenomegaly. 
Statistical significance was seen when comparing the median sizes in all 3 diseases but no difference 
was seen between the ET and PV group of patients. Furthermore the p values also show that the 
median size of the spleen in PMF was significantly larger than ET or PV.      
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3.3.3 ANALYSIS OF SIZE OF SPLENOMEGALY IN PMF 
Table 5: Frequency of different sizes of splenomegaly in PMF 
SPLENOMEGALY IN PMF Number (%) 
  
PMF Patients 41 (98%) 
  
< 4 cm below costal margin 11(27%) 
  
4-8 cm below costal margin 14 (34%) 
  
> 8 cm below costal margin 16 (39%) 
 
It is clearly demonstrated that splenomegaly is almost always present in patients with PMF in this 
cohort (98%). Table 5 also shows that the majority of PMF patients present with moderate to massive 
splenomegaly (73%), while 27% of patients present with mild splenomegaly. 
 
 
3.4 ANALYSIS OF BLOOD RESULTS ON PRESENTATION 
Most patients presenting to the hospital for investigation would have a battery of tests done to aid 
the physician in diagnosis. The pertinent blood tests assessed in patients with MPN include a Full Blood 
Count (with examination of the peripheral blood smear), haematinic analysis (including iron studies, 
red cell folate and vitamin B12), serum uric acid, as well as serum erythropoietin (in patients suspected 
of PV) prior to the era of the JAK2 V617F mutation analysis. Tables 6, 7, and 8 show blood results 
obtained at presentation for patients diagnosed with ET, PV, and PMF respectively. Where the 
distribution of values were skewed, the median was utilised, while the mean was utilised for values 
with a normal pattern of distribution.  
 
The median White Cell Count for ET was elevated at 12,23 x 10⁹/l, however the mean counts for PV 
and PMF were in the normal reference range. Mean Haematocrit (Hct) values were predictably high 
in patients with PV at 0,63 l/l, and normal reference values were seen in ET and PMF. The mean 
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Haemoglobin value in ET was 12,26 g/dl, but the mean value in PMF was 8,3 g/dl. Thrombocytosis was 
again predictably seen in patients presenting with ET, with a mean platelet count of 1250 x 10⁹/l. 
Examination of the peripheral blood smear showed that teardrops were present in 73% of patients 
with PMF, while a leucoerythroblastic picture was seen in 21% of these patients. On analysing the 
values of the iron studies there were 9 patients that were iron deficient (5 with PMF and 2 with PV 
and ET respectively), but median ferritin values for all 3 groups were within the normal reference 
range. Folate deficiency was recorded in 4 patients with ET and 5 patients with PMF, but not in any 
patient with PV. Only 1 patient was diagnosed as having Vitamin B12 deficiency in the PMF group.   
 
 
Human Immunodeficiency Virus (HIV) Elisa testing was undertaken in 76% of all patients diagnosed 
with MPN. A very low proportion of patients were infected with the virus, with only 2 patients with ET 
and 1 patient with PMF being diagnosed as HIV positive. Serum Erythropoietin (EPO) levels were 
measured in 70% of patients with PV with a median of 3,2 mU/ml, which is decreased according to 
the reference range used.  
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Table 6: Analysis of Blood Results of patients diagnosed with ET 
   
ET Number Values  (n = normal) 
   
WCC ( x 10⁹/l ) ( mean ± SD ) N=35 12,23 ± 4,66   (n= 4 – 10) 
   
RCC ( x 10¹²/l ) ( mean ± SD ) N=13 4,74 ± 1,23   (n= 3,9 – 5,8) 
   
Hct ( l/l ) ( mean ± SD ) N=33 0,39 ± 0,09  (n= 0,43 – 0,55) 
   
Hb ( g/dl ) ( mean ± SD ) N=35 12,26 ± 2,93  (n= 11,6 – 17,5) 
   
MCV (fl) ( mean ± SD ) N=35 81,92 ± 8,12  (n= 79 – 101) 
   
Platelets ( x10⁹/l) ( mean ± SD ) N=35 1250 ± 462  (n= 170 – 450) 
   
Fe ( µmol/l ) ( median ± IGR ) N=32 7,9 (1-33)  (n= 10 – 30) 
   
Sat Fe ( % ) (mean ± SD ) N=30 13,86 ± 8,1  (n= 25 – 50) 
   
Transferrin ( g/l ) ( mean ± SD ) N=33 2,53 ± 0,70  (n= 2 – 3,6) 
   
Ferritin ( µg/ml ) ( median ± IGR ) N=33 54 (14-1901)  (n= 30 – 400) 
   
HIV positive  2 
   
HIV negative  22 
   
HIV unknown  11 
   
RC folate ( nmol/l ) ( median ± IGR ) N=23 541 (82-4706)  (n= 418 – 1158) 
   
Vitamin B12 ( pmol/l ) ( mean ± SD ) N=24 471 ± 189  (n= 145 – 637) 
   
Uric acid ( mmol/l ) ( median ± IGR ) N=26 0,37 (0,2-1,18)  (n= 0,22 – 0,45) 
 
 (WCC = White Cell Count, RCC = Red Cell Count, Hct = Haematocrit, Hb = Haemoglobin, MCV = Mean 
Cell Volume, Fe = Iron, Sat Fe = % Iron Saturation, RC folate = Red Cell folate)   
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Table 7: Analysis of Blood Results of patients diagnosed with PV 
 (WCC = White Cell Count, RCC = Red Cell Count, Hct = haematocrit, Hb = Haemoglobin, MCV = Mean 
Cell Volume, Fe=Iron, Sat Fe =% Iron Saturation, RC folate = Red Cell folate, EPO = serum 
erythropoietin) 
PV Number Values (n = normal) 
   
WCC ( x 10⁹/l ) ( median ± IGR ) N=17 8,01 (4,6-42,5)  (n= 4 – 10) 
   
RCC ( x 10¹²/l ) ( mean ± SD ) N=14 7,46 ± 1,13  (n= 3,9 – 5,8) 
   
Hct ( l/l ) ( mean ± SD ) N=17 0,63 ± 0,05  (n= 0,43 – 0,55) 
   
Hb ( g/dl ) ( mean ± SD ) N=17 20,6 ± 2,4  (n= 11,6 – 17,5) 
   
MCV ( fl ) ( mean ± SD ) N=17 83,9 ± 9,9  (n= 79 – 101) 
   
Platelets ( x 10⁹/l ) ( mean ± SD ) N=17 371 ± 240  (n= 170 – 450) 
   
Fe ( µmol/l ) ( median ± IGR ) N=12 8,95 (3,2-30,9)  (n= 10 – 30) 
   
Sat Fe ( % ) ( median ± IGR ) N=10 11 (4-40)  (n= 25 – 50) 
   
Transferrin ( g/l ) ( mean ± SD ) N=12 2,96 ± 0,76  (n= 2 – 3,6) 
   
Ferritin ( µg/ml ) ( median ± IGR ) N=12 45,5 (15-1667)  (n= 30 – 400) 
   
HIV positive  0 
   
HIV negative  13 
   
HIV unknown  4 
   
RC folate ( nmol/l ) ( median ± IGR ) N=9 785 (336-8408)  (n= 418 – 1158) 
   
Vitamin B12 ( pmol/l ) ( median ± IGR ) N=11 499 (323-1462)  (n= 145 – 637) 
   
Uric acid ( mmol/l ) ( mean ± SD ) N=13 0,52 ± 0,17  (n= 0,22 – 0,45) 
   
PaO₂ ( mmHg ) ( mean ± SD ) N=6 80 ± 8  (n= 69 – 84) 
   
Sats O₂ ( % ) ( mean ± SD ) N=6 94 ± 2  (n= 90 – 98) 
   
Serum EPO (mU/ml) ( median ± IGR ) N=12 3,2 (1,2-11,6)  (n= 4,1 – 19,5) 
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Table 8: Analysis of Blood Results of patients diagnosed with PMF 
 
 (WCC = White Cell Count, RCC = Red Cell Count, Hct = Haematocrit, Hb = Haemoglobin, MCV = Mean 
Cell Volume, Fe = Iron, Sat Fe = % Iron Saturation, RC folate = Red Cell folate) 
PMF Number Values  (n = normal) 
   
WCC ( x 10⁹/l ) ( median ± IGR ) N=42 9,3 (1,5-90,5)  (n= 4 – 10) 
   
RCC ( x 10¹²/l ) ( mean ± SD ) N=24 3,01 ± 0,9  (n= 3,9 – 5,8) 
   
Hct ( l/l ) ( mean ± SD ) N=35 0,26 ± 0,07  (n= 0,43 – 0,55) 
   
Hb ( g/dl ) ( mean ± SD ) N=42 8,3 ± 3  (n= 11,6 – 17,5) 
   
MCV ( fl ) ( mean ± SD ) N=42 84,8 ± 8  (n= 79 – 101) 
   
Platelets ( x 10⁹/l ) ( mean ± SD ) N=42 231 ± 203  (n= 170 – 450) 
   
Fe ( µmol/l ) ( median ± IGR ) N=32 9,1 (1,3-46)  (n= 10 – 30) 
   
Sat Fe ( % ) ( median ± IGR ) N=23 20 (3-94)  (n= 25 – 50) 
   
Transferrin ( g/l ) ( median ± IGR ) N=31 2 (1-20)  (n= 2 – 3,6) 
   
Ferritin ( µg/ml ) ( median ± IGR ) N=32 276 (18-2247)  (n= 30 – 400) 
   
HIV positive  1 
   
HIV negative  34 
   
HIV unknown  7 
   
RC folate ( nmol/l ) ( median ± IGR ) N=25 590 (142-4103)  (n= 418 – 1158) 
   
Vitamin B12 ( pmol/l ) ( median ± IGR ) N=27 741 (54-2000)  (n= 145 – 637) 
   
Uric acid ( mmol/l ) ( median ± IGR ) N=27 0,45 (0,24-1,21) (n= 0,22 – 0,45) 
   
Leucoerythroblastic picture on smear N=33 7 patients 
   
Teardrops on smear N=33 24 patients 
   
Blasts on smear N=33 30 patients 
 39 
 
Table 9: Prevalence of hyperuricaemia in patients with Ph1 negative MPN  
 
HYPERURICAEMIA ET PV PMF 
    
 NUMBER TESTED 26 13 27 
    
INCREASED URIC ACID 
LEVEL 12 (46%) 10 (77%) 10 (37%) 
    
GOUT 1 (3%) 2 (12%) 2(5%) 
(normal serum uric acid 0,22 – 0,45 mmol/l ) 
(for patients with gout – ET (N = 35), PV (N = 17), PMF (N = 42)) 
 
In MPN, uric acid production is increased. Serum uric acids levels were tested in 70% of patients. 
Seventy seven percent of patients with PV had hyperuricaemia while 46% and 37% of serum uric acid 
levels were raised in ET and PMF respectively. Hyperuricaemia seems to be more commonly seen in 
PV than in ET or PMF. However, the development of gout was uncommon, with only 5% of all patients 
having been diagnosed with this condition.  
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3.5 PREVALENCE OF THE JAK2 V617F MUTATION 
Table 10: Analysis of the Prevalence of JAK2 V617F Mutation in patients with Ph1 
negative MPN 
JAK2 V617F MUTATION ET PV PMF ALL PATIENTS 
     
NUMBER OF PATIENTS 35 17 42 94 
     
POSITIVE 11 8 8 27 
     
NEGATIVE 0 1 1 2 
     
UNKNOWN 24 8 33 65 
 
JAK2 V617F mutation is measured by Polymerase Chain Reaction (PCR) analysis. The test became 
available to the NHLS in 2005. A total of 29 patients (31%) were tested in this cohort. 11 patients with 
ET that were tested had the mutation while 8 patients with PV and PMF were to shown to be JAK2 
V617F mutation positive (as illustrated in table 10). 4 patients that were tested did not have the 
mutation. Unfortunately a large proportion of patients were not tested for the mutation, probably 
due to the fact that the test was not discovered and not available prior to 2005. 
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Figure 13: JAK2 V617F Mutation in ET according to year of presentation 
  
 
Figure 14:  JAK2 V617F Mutation in PV according to year of presentation 
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Figure 15: JAK2 V617F Mutation in PMF according to year of presentation 
 
Figures 13, 14, and 15 illustrate the results of the JAK2 V617F mutation analysis of patients in the year 
of presentation. As demonstrated, most tests were done between the years 2006 – 2011. In the ET 
group, 8 patients tested as positive between these years while 5 PV patients and 8 PMF patients also 
tested positive during this time period. It is now routine practice to test all patients suspected of 
having MPN by doing the JAK2 V617F mutation analysis.       
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3.6 SUPPORTIVE MANAGEMENT 
Table 11: Analysis of Supportive Treatment used in MPN 
 All Patients (N=94) ET (N=35) PV (N=17) PMF (N=42) 
     
Folate 56 (60%) 21 (60%) 1 (6%) 34 (81%) 
     
Iron 30 (32%) 5 (14%) 1 (6%) 24 (57%) 
     
Allopurinol 66 (70%) 31 (89%) 13 (76%) 22 (52%) 
     
Anticoagulation 10 (11%) 4 (11%) 5 (29%) 1 (2%) 
     
Aspirin 16 (17%) 13 (37%) 3 (18%) 0 (0%) 
     
Venesection 17 (18%) 0 (0%) 17 (100%) 0 (0%) 
     
Blood 
Transfusion 27 (29%) 6 (17%) 0 (0%) 21 (50%) 
 
 
A summary of the supportive treatment used is illustrated in Table 11. Folate tablets were given to 
60% of all patients, with a large number of the 42 PMF patients receiving the drug. Iron 
supplementation was also most commonly given to patients with PMF with 57% of these patients 
having received either oral or intravenous replacement. Allopurinol was administered to 70% of 
patients with MPN. Anticoagulation in the form of warfarin or low molecular weight heparin was 
prescribed to 11% of patients. Aspirin was prescribed to 37% of ET patients, and 18% of patients with 
PV. Other supportive treatment included phlebotomy or venesection, as well as blood transfusions. 
Venesection is therapeutic in patients with PV and thus 100% of patients with PV were venesected. A 
total of 50% of PMF patients needed a blood transfusion. A small proportion of ET patients (17%) were 
also recorded as requiring a blood transfusion.    
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3.7 SPECIFIC MANAGEMENT 
Table 12: Analysis of Drugs used to treat MPN 
DRUGS USED ET ( N=35) PV (N=17) 
PMF 
(N=42) ALL (N=94) 
     
Hydroxyurea 32 (91%) 9 (53%) 24 (57%) 65 (69%) 
     
Anagrelide 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
     
32P 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
     
Busulphan 9 (26%) 1 (6%) 2 (5%) 12 (13%) 
     
Corticosteroids 1 (3%) 0 (0%) 7 (17%) 8 (9%) 
     
Danazol 0 (0%) 0 (0%) 5 (12%) 5 (5%) 
     
Interferon alpha 2 (6%) 0 (0%) 0 (0%) 2 (2%) 
     
Other* 1 (3%) 0 (0%) 0 (0%) 1 (1%) 
 (*Ruxolitinib) 
 
The analysis of specific drugs used to treat MPN is demonstrated in Table 12. The most common 
specific treatment used in this cohort was hydroxyurea, with 91%, 53% and 69% of patients with ET, 
PV, and PMF receiving it respectively. In the earlier period of this study, busulphan was used as an 
alternative to hydroxyurea, especially in ET, with 26% of patients receiving this drug. Only 1 PV patient 
and 2 PMF patients in this cohort were given busulphan. 17% of PMF patients were prescribed 
corticosteroids in the form of oral prednisone, and only 1 patient with ET received it. Other drugs used 
either as an alternative or as an additional drug were danazol and interferon alpha. These were also 
among the least used drugs with only 2 patients receiving interferon alpha, while danazol was used in 
5 patients (12%) of patients with PMF. 1 patient from the ET group was put on a trial using the JAK 
inhibitor called ruxolitinib. Anagrelide and 32P were not used in this cohort.  
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3.7.1 NUMBER OF DRUGS USED 
 
 
Figure 16: Number of Drugs used to treat ET 
 
 
Figure 17: Number of Drugs used to treat PV 
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Figure 18: Number of drugs used to treat PMF 
 
Figures 16, 17, and 18 illustrate the number of drugs used by patients with MPN in this cohort. The 
majority of patients with ET (63%) were treated with only drug i.e. hydroxyurea, while 6 patients were 
given 2 drugs simultaneously, and only 1 patient received 3 or 4 drugs at one time. Similar findings 
were observed in the PV and PMF groups, as it was common practise to use 1 drug (7 PV patients and 
26 PMF patients). Danazol was utilised as a single drug in 3 PMF patients and another 4 PMF patients 
were prescribed corticosteroids as a single drug.  
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3.7.2 DURATION OF SPECIFIC TREATMENT USED 
Tables 13 and 14 depict the duration of specific drugs used during the course of disease in patients 
with ET and PMF. A hundred percent of patients with PV were venesected, and 41% of PV patients 
were treated with hydroxyurea alone with a median duration of 207 days. 22 patients with ET were 
treated with hydroxyurea alone with a median duration of 226,5 days. Patients refractory to 
hydroxyurea were then initiated on busulphan, as was observed in 6 patients. Only 1 patient with ET 
received 3 drugs, with interferon alpha being used after the patient did not respond to hydroxyurea 
and busulphan. Hydroxyurea was used alone to treat patients with PMF in 45% of cases. The median 
duration of treatment in this group was 99 days. Danazol was also used in patients with PMF in 7% of 
cases with a median duration of 43 days. Other drugs used were corticosteroids in 4 patients with 
PMF, with the median duration of treatment being two and half months. Hydroxyurea was the most 
common specific drug treatment used in patients with MPN.   
 
 
Table 13: Duration (in days) of specific treatment in patients with ET (N=30) 
 
 
Only 
Hydroxyurea 
 
 
Hydroxyurea + 
Busulphan 
 
 
Hydroxyurea + 
Busulphan + 
Interferon 
alpha 
 
Hydroxyurea +  
Busulphan + 
Interferon 
alpha + 
Ruxolitinub 
Number 22 6 1 1 
Duration of 
hydroxyurea 226,5(22-2630)* 1252,5(57-5142)* 
          3358 
 
2401 
 
Duration of 
Busulphan  
31(4-771)* 
 
259 
 
273 
 
Duration of 
Interferon alpha   
1134 
 
519 
 
Duration of 
Ruxolitinib    
126 
 
*(median ± IGR utilised when patient number >2) 
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Table 14: Duration (in days) of specific treatment in patients with PMF (N=29) 
 
 
Only 
Hydroyxurea 
Hydroxyurea 
+ busulphan 
Hydroxyurea + 
Corticosteroids 
Only 
Corticosteroids 
Only 
Danazol 
Number 19 1 2 4 3 
Duration of 
Hydroxyurea 99(7-1366)* 1177 400   
Duration of 
Busulphan  372    
Duration of 
Corticosteroids   529,5 81(43-239)*  
Duration of 
Danazol     
43(40-
211)* 
*(median ± IGR utilised when patient number > 2) 
 
 
3.8 RESPONSE TO TREATMENT 
 
Figure 19: Platelets at Presentation vs Platelets Best recorded in ET 
(P value = < 0,0001 using paired t-test) 
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Figure 19 (above) depicts the response of treatment in ET patients, by comparing the 
presenting platelet counts to the best recorded platelet counts. On viewing the line graph, it 
is seen that the best platelet count recorded are definitely lower than the presenting counts. 
This suggests that the treatment used is effective in lowering platelet counts in ET patients. 
The p value is also statistically significant and supports this notion. 
 
Figure 20 (below) illustrates the response to treatment in patients with PV by comparing the 
presenting Hct levels against the best recorded Hct levels. Once again the line graph is 
indicative of lower Hct values recorded post treatment. The p value demonstrates a statistical 
significance and therefore also reveals that treatment used in PV was effective in decreasing 
the Hct in patients diagnosed with PV.  
 
 
Figure 20: Haematocrit at Presentation vs Haematocrit Best recorded in PV 
(Hct = Haematocrit) 
(p value = 0,0001 using paired t test) 
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Table 15: Analysis of Venesections in patients with PV 
 
Venesections in Patients with PV  
  
Number of patients venesected (%) 17 (100%) 
Average number of venesections per patient 9 ±6 
Median (± IGR) days per venesection 117 (15-1216) 
 
As previously demonstrated, venesection was carried out in 100% of patients with PV, with 
the aim of lowering the haemoglobin, red cell count, and Hct, thereby lowering the blood 
viscosity and thus reducing the incidence of complications. The average number of 
venesections performed per patient in this cohort was 9 times. It was also noted that there 
was a median duration of approximately 4 months between each venesection. From these 
records it is suggestive that venesection therefore plays a pivotal role in the treatment of PV.   
 
3.9 COMPLICATIONS OF MPN 
Figure 21 illustrates the complications of MPN that occurred in patients in this cohort. Thrombotic 
complications include strokes, the occurrence of deep vein thrombosis and pulmonary thrombo – 
embolic disease, as well as intra-abdominal thrombus formation. The most common complication was 
bleeding (which included gingival bleeds, epistaxis and conjunctival haemorrhages) and this was 
demonstrated in 19% of all patients. 24% and 17% of PMF and ET patients suffered from a bleed 
respectively, while only 12% of PV patients were recorded as having a bleeding episode. Stroke 
occurred in 4 ET and PV patients, while no patients diagnosed with PMF had this debility. Only 3% of 
all patients developed deep vein thrombosis (2 PV patients) or a pulmonary embolus (1 patient in the 
PV, ET, and PMF group). Intra-abdominal thrombosis in the form of splanchnic vein thrombosis was 
diagnosed in only 2 (6%) of all ET patients.  
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Figure 21: Frequency of Complications occurring in MPN 
(DVT = Deep Vein Thrombosis, PTED = Pulmonary Thrombo-embolic Disease) 
 
3.9.1 TRANFORMATION ANALYSIS 
Table 16: Frequency of Transformation in Ph1 Negative MPN 
 ET  PV PMF  
    
To ET -- 0 0 
To PV 0 -- 0 
To MF 2 (6%) 2 (12%) -- 
To AML 2 (6%) 0 6 (14%) 
 
Another complication of MPN is the ability to transform into another form of MPN, as well as the fatal 
leukaemic transformation. Table 16 illustrates the frequency of transformation in this cohort. Disease 
transformation is shown to be an uncommon occurrence in this cohort, however, when it did occur, 
it was seen from ET and PV to myelofibrosis in 6% and 12% of patients respectively. Transformation 
to acute myeloid leukaemia was documented in 14% of patients with PMF and 6% of patients with ET. 
Stroke DVT
Peripheral
Vascular
Disease
PTED
Splanchnic
Vein
Thrombosis
Bleeding
ET (N=35) 4 0 1 1 2 6
PV (N=17) 4 2 1 1 0 2
PMF (N=42) 0 1 0 1 0 10
0
2
4
6
8
10
12
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3.10 OUTCOMES 
The final clinico-haematologic responses of patients diagnosed with MPN were analysed using 
criteria suggested by the ELN working group. The major outcomes included complete 
response, partial response, and no response which was further subdivided into stable disease 
and death.  
 
3.10.1 OUTCOMES OF PATIENTS TREATED 
Table 17: Final Outcomes of ET, PV, and PMF 
 ALL (N=94) ET (N=35) PV (N=17) 
PMF 
(N=42) 
     
Complete 
Response 5 (5%) 1 (3%) 2 (12%) 2 (5%) 
     
Partial Response 7 (8%) 6 (17%) 1 (6%) 0 (0%) 
     
Relapse 1 (1%) 0 (0%) 0 (0%) 1 (2%) 
     
Stable Disease 52 (55%) 21 (60%) 12 (70%) 19 (45%) 
     
Death 29 (31%) 7 (20%) 2 (12%) 20 (48%) 
 
Table 17 depicts the final outcomes based on the best documented outcome at the last visit 
in patients with MPN. Overall the results documented reveal that the outcomes of treatment 
available to patients in this cohort was dismal. A total of 5% of patients showed a complete 
response in this cohort and only 7% of all patients had a partial response. The most promising 
results may have come from the ET group with 17% of patients being recorded as having a 
partial response. 55% of all patients had stable disease on treatment, with 60% of ET patients, 
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70% of PV patients, and 45% of PMF patients belonging to this group. A total of 31% of MPN 
patients in this cohort died, and the worst outcomes were seen in the PMF group as 48% of 
these patients lives ended in death. Death came about to only 2 patients with PV, however 
20% of patients in the ET group also had a final outcome of death. The criteria recommended 
by the ELN seem to be quite stringent and therefore there was difficulty in maintaining a 
persistent complete response. However most of the patients were clinically stable during the 
course of the disease, even though many fluctuations of laboratory parameters were seen. 
 
3.10.2 SURVIVAL CURVES 
 
Figure 22: Survival Curves for ET, PV, and PMF 
p value = 0,0079 (Chi² using log ranks (Mantel-Cox) analysis) 
 
 
The survival curves of patients diagnosed with ET, PV, and PMF is depicted in Figure 22. On analyses 
of the survival curves, it is safe to say that PV and ET have a better chance of survival than PMF as the 
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disease progresses. The 5 year survival of PV was 80%, while the worst 5 year survival belongs to the 
PMF group with a 40% survival being illustrated. ET has the best 5 year survival in this cohort with 
85%, however as time progresses it is shown that the percentage of survival decreases substantially 
to around 52% (15 year survival).  
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CHAPTER 4: DISCUSSION 
4.1 INTRODUCTION 
Myeloproliferative Neoplasms collectively represent a disease entity that was initially described as 
early as the 1950’s (1). MPN are clonal proliferations of the 3 main blood cells lines and manifest with 
features of thrombosis and bleeding. Essential Thrombocythaemia, Polycythaemia Rubra Vera, and 
Primary Myelofibrosis differ from Chronic Myeloid Leukaemia in that they do not exhibit the 
Philadelphia Chromosome. Compared to CML, the other MPN mentioned above have been less well 
characterized. A retrospective analysis of the 3 Philadelphia Chromosome Negative Myeloproliferative 
Neoplasms was thus undertaken to better understand the patterns of the disease in this group, 
including the efficacy of treatment based on our management. The study reviewed 94 patients 
diagnosed with Ph1 negative MPN at Chris Hani Baragwanath Academic Hospital between 1987 and 
2011 (25 years). 
 
 4.2 EPIDEMIOLOGY 
During the 25 year period, 94 patients were diagnosed with a MPN, using criteria recommended by 
the Polycythaemia Study Group in the early years, and revised WHO criteria in 2001 and 2008 (115) 
(116). Of the patients studied, 45% were diagnosed with PMF, while 37% of the patients were 
diagnosed with ET, and 18% with PV. These figures differ from studies carried out in Europe and the 
United States where PV was shown to be the most common diagnosis and PMF the least common (53) 
(117). The reason for this difference is not entirely clear but could be due to PV being relatively benign 
and being managed by general physicians, while most of the PMF patients are referred to a specialised 
centre for further management. The ethnic group may also play a role. Many of the studies undertaken 
in Europe involve mostly Caucasian patients, while the vast majority of patients in this cohort are of 
African descent.  
 
 
The median age at diagnosis of MPN was 61,5 years. Similar median ages to the MPN group were seen 
in the ET and PMF groups with 63 and 63,5 years respectively. However the median age of diagnosis 
at presentation was 54 years, almost a decade younger, in patients with PV. Our findings are similar 
to other cohorts where MPN has been shown to occur between the ages of 50 to 70 years, with a 
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median age of presentation of 61 years in patients with PV noted in one study, while median ages of 
66 years for PMF and 54 years for ET were found in studies carried out at the Mayo Clinic (118) (119) 
(61). Thus, overall one can conclude that MPN is a disease most commonly of middle aged individuals.  
 
 
The study also revealed that there is no significant gender disparity in the whole MPN group with a 
male to female ratio of 1: 1.24. However, twice as many females compared to males were seen in the 
ET group, while an equal number of males and females were diagnosed with PMF. A review of patients 
with MPN carried out in Sweden revealed a slight male predominance of 53% while studies at the 
Mayo Clinic showed a female predominance in the PMF group. 
 
4.3 SYMPTOMATOLOGY 
Symptoms associated with MPN are due to the features of the disease process. The most common 
symptom recorded in an online survey of 1179 patients is fatigue with 81% having complained of this 
symptom respectively (45). Other symptoms that patients complained about were pruritus and night 
sweats (52% and 49%), as well as bone pain, fever and weight loss (44%, 14% and 13% respectively) 
(45). Fatigue was also the most common symptom in our cohort with 85% of patients presenting with 
this symptom. Other common symptoms included weight loss and night sweats, which are 
constitutional symptoms. In our setting, other causes of constitutional symptoms such as HIV, 
tuberculosis and lymphomas must be excluded. Pruritus is another well-known symptom of MPNs, 
especially PV, and our cohort shows no difference, with 59% of PV patients presenting with this 
complaint. Erythromelalgia is an uncommon symptom as indicated in studies in the United States and 
in Norway, and this is also seen in our cohort with only 1 patient presenting with this complaint (120) 
(121). Thus, the presenting symptoms of patients with MPN in our cohort is similar to that published 
in the literature. 
 
4.4 CLINICAL FEATURES 
The occurrence of increased erythropoiesis, megakaryopoiesis, and fibrosis in the bone marrow leads 
to a variety of clinical features that may lead to increased morbidity and mortality in patients with 
MPN. These clinical features include organomegaly secondary to extramedullary haemopoiesis, as 
well as pallor and clinical evidence of bleeding due to progressive cytopenias. It is well demonstrated 
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in the literature that splenomegaly is a common clinical feature of MPN, especially in PMF. This is well 
illustrated in this cohort, as splenomegaly was the most common presenting clinical feature in 80% of 
the patients. All but 1 patient with PMF (98%) were recorded as having a splenomegaly on clinical 
examination. Splenomegaly leads to increased patient distress, caused by abdominal discomfort and 
pain, as well as compounding the effects of cytopenias due to splenic sequestration (122). The median 
size of the spleen palpated below the costal margin in PMF was 7cm and 73% of all PMF patients were 
shown to have a moderate to massive splenomegaly. This is in contrast to PV and ET patients who 
demonstrated median spleen sizes reflecting a small splenomegaly (< 4cm). This is also in keeping with 
findings in the literature. Symptomatic splenomegaly has been managed with different modalities of 
treatment such as hydroxyurea, radiotherapy, splenectomy and more recently the JAK2 inhibitors 
(122) (123). This will aim to reduce the size of the spleen and alleviate distressing pain as well as reduce 
the effects of hypersplenism. Hepatomegaly may be due to extramedullary haemopoeisis. 
Hepatomegaly is a common finding especially in PMF patients. More prominent hepatomegaly was 
found in this cohort in the PMF group compared to ET and PV groups.  
 
 
Excessive bleeding due to platelet hypoactivity and dysfunction as well as thrombocytopenia may lead 
to anaemia, especially in patients with PMF. As the PMF progresses, excessive bone marrow fibrosis 
may occur, leading to cytopaenias. This manifests clinically as pallor, bleeding, petechiae, purpura, 
and ecchymosis. Pallor was evident in 78% of PMF patients in our study, which signifies that it is a 
common feature at presentation. Only 12% of the whole cohort presented with clinical evidence of 
petechiae, purpura or ecchymosis, which is in keeping with a study of cutaneous manifestations of ET 
in the United States, where 10% of patients presented with these features (124). Twelve patients in 
our study were recorded as having changes such as tortuous and dilated retinal vessels seen in PV 
from increased blood volume, and also haemorrhages of the retinal vessels which may also be 
observed (125). Lymphadenopathy was palpated in 12% of patients in our cohort and could be linked 
to other diseases such as HIV, tuberculosis, or even other viral infections. Lymphoproliferative 
disorders have been reported occasionally to be associated with MPN as shown in a study by 
Vannucchi et al (126). Lymphadenopathy is not a typical feature of MPN, and its presence should 
generally suggest another cause. 
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4.5 ANALYSIS OF BLOOD RESULTS 
Haematological diseases are never assessed without the analysis of blood results in the patients 
affected. A diagnosis of MPN cannot be made unless relevant abnormalities are demonstrated and 
this is also the reason why many patients are referred to a specialised Haematology unit for further 
investigation. The occurrence of clonal proliferation of the erythropoietic and megakaryopoietic cell 
lines can be demonstrated on full blood counts and other important features can be shown on bone 
marrow investigation. Criteria for diagnosis of the Ph1 negative MPN have been revised in 2008 by the 
WHO (127). A platelet count of > 450 x 10⁹/l is one of the criteria for ET and this is evident in our study 
with a mean platelet count of 1250 x 10⁹/l at presentation. A similar study in Europe showed an 
average platelet count of 897 x 10⁹/l at presentation (128). Leucocytosis was shown in the majority of 
the ET patients in this cohort with a mean of 12,23 x 10⁹/L. The importance of this was demonstrated 
in a study by Carobbio et al, where leucocytosis was shown to be a risk factor for future thrombotic 
events in patients diagnosed with ET (129). The number of platelets though were not associated with 
any thrombotic risk, however a platelet count > 1500 x 10⁹/l is associated with a form of acquired von 
Willebrand’s disease, and thus an increased risk of bleeding (130).  
 
 
Criteria for PV includes erythrocytosis with raised haemoglobin levels associated with low serum 
erythropoietin levels. Our cohort had a mean haemoglobin of 20,6 g/dl and a mean haematocrit of 
0,63 l/l. Treatment recommendations are clear about reducing the haematocrit level to < 0,45 l/l as 
levels higher than this pose an increased risk for cardiovascular complications (131). Other factors of 
note were that neither the mean platelet or leucocyte counts were raised in PV patients. Very few 
patients in our study had oxygen saturation values recorded. Serum EPO levels are important in 
differentiating primary from secondary polycythaemia. Low serum EPO levels in patients suspected of 
PV helped considerably with the diagnosis in the past (this is largely replaced by JAK2 617F mutation 
analysis) while if the serum EPO levels are raised, then one has to suspect secondary causes of 
erythrocytosis such as chronic obstructive pulmonary disease. The median serum EPO levels in our 
cohort was 3,2 mU/ml, which is decreased according to our reference ranges (4,1-19,5 mU/ml) and 
correlates with the diagnosis of PV.  
 
 
Features of decreased erythropoiesis and reticulin or collagen fibrosis in the bone marrow is a major 
criteria for the diagnosis of PMF. However, other features on the full blood count include an anaemia 
as well as a leucoerythroblastic picture on examination of the peripheral blood smear. Due to possible 
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poor or incomplete recording of patient results in our cohort by the attending physicians, only 7/42 
patients (16,7%) had a leucoerythroblastic picture, while studies elsewhere do reveal that it is a 
common occurrence in PMF patients (132). Another common finding in the peripheral blood smear is 
of teardrop shaped red blood cells, and this correlates with our study as 72% of patients with PMF had 
this finding (133). Anaemia was found in the majority of patients with PMF (90,4%), likely due to 
multifactorial causes including reduced erythropoiesis, with a mean value of 8,3 g/dl. The IPSS is used 
to assess the prognosis of PMF patients at presentation while the DIPSS is used at any point in the 
disease process. These prognostic indices are predictors of inferior survival and include age > 65 years, 
haemoglobin < 10 g/dl, constitutional symptoms, leucocytosis of > 25 x 10⁹/l, evidence of blasts > 1% 
and other factors such as transfusion requirements, unfavourable karyotype and platelets < 100 x 
10⁹/l (134). On further assessment of our cohort, patients referred to the Haematology unit that are 
diagnosed with PMF have an IPSS score of at least 3, which  puts them in the high risk category and 
thus suggests poor prognosis (135).  
 
 
Five patients in the study were iron deficient from factors other than bleeding related to MPNs. Three 
patients were HIV seropositive. This is likely to be coincidental rather than causal. The majority of 
patients with PV (77%) presented with hyperuricaemia. However, only two patients in this group and 
only 5 patients overall (with Ph1 negative MPN) developed secondary gout. This could be due to early 
and routine initiation of xanthine oxidase inhibitors like allopurinol in our patients (136).   
 
4.6 JAK2 V617F MUTATION PREVALENCE  
The discovery of the V617F mutation of Janus Kinase 2 in 2005 has changed the diagnostic landscape 
of MPN and is also impacting on therapy of the MPN. The PCR test for this mutation has been available 
in South Africa since 2006 and thus new patients and old patients were able to undergo this 
investigation and the diagnosis of MPN has been made easier and clearer. The presence of this 
mutation has also been introduced into the revised WHO criteria, thereby improving the diagnostic 
criteria for these diseases (2). Other mutations have also been discovered which alter the way the 
disease has been assessed in patients with ET and PMF especially. These mutations include the MPL 
and CALR mutations, and are thought to explain why some patients who do not have the JAK2 V617F 
mutation still present with a MPN (137). The frequencies of the JAK2 V617F mutation in the Ph1 
negative MPN are estimated at approximately 98% of all PV patients, while at least 50 - 60% of patients 
with ET and PMF will have the mutation (137). The JAK2 V617F mutation has other implications 
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including an increased risk of leukaemic transformation as well as increased risk of thrombotic events 
(138) (139). In our study 29 patients were tested for the mutation, with 27/29 patients (93%) having 
a positive result and 2 patients a negative result. This leaves a significant proportion of patients who 
have an unknown JAK2 V617F mutation status (these are patients who may have died or were lost to 
follow up) and thus it was difficult to compare and analyse the significance of the mutation between 
the patients. 
 
 
The investigation for the JAK2 V617F mutation in patients suspected of a MPN is now readily available 
and thus should be done in all patients at presentation. This will give us a better idea of the frequency 
of this mutation in MPN in our setting and help with diagnostic difficulties. Newer treatment aimed at 
JAK2 inhibition are still underway, however JAK2 inhibitors like Ruxolitinib has already been approved 
for myelofibrosis (140).  
 
4.7 MANAGEMENT OF MPN 
Therapy for MPN includes both supportive care and specific modalities such as cytoreductive therapy, 
targeted therapy and allogeneic stem cell transplantation. There has been no cure reported for MPN, 
and treatment is aimed at alleviation of symptoms and lessening disease burden, as well as reducing 
the risk of fatal complications.  
 
 
Red cell folate deficiency was noted in 9/94 patients (9,6%) in our cohort, 5/42 (12%) of them 
belonging to the PMF group. Folate deficiency has been associated with MPN, likely secondary to 
ineffective haemopoeisis or due to drugs that antagonize folate, and due to increased cell turnover, 
which results in an increased utilization of folate. It is more common in PMF (141). Folate 
supplementation was prescribed to 81% of PMF patients and 60% of ET patients, in our study.  
 
 
The occurrence of vascular events are most common in PV and ET and thus therapy aimed at reducing 
this includes aspirin. The ECLAP trial demonstrated that patients with PV benefitted from the use of 
aspirin, by reducing thrombotic events and with no significant risk of fatal bleeding (67). Only 16% of 
all patients were given aspirin (this was exclusively in the ET and PV patients). Patients with MPN may 
also have other comorbities such as hypertension or diabetes mellitus, which could also contribute to 
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thrombotic risk. Iron deficiency is not commonly seen in MPN, except for patients with PV receiving 
regular venesection, however, patients with evidence of bleeding may develop iron deficiency. Only 5 
patients in our cohort had iron deficiency. However, oral iron supplementation was given to 57% of 
PMF patients as one of the measures to improve their anaemia. 
 
 
Blood transfusions are most commonly required in patients with PMF as observed in our study. 
Transfusions are required for symptomatic anaemia. The need for blood transfusions were seen in 
50% of patients with PMF during the course of their disease, and according to the DIPSS indicates a 
worse prognosis (134). Only 6 patients from the ET group required a blood transfusion, either due an 
acute bleed or secondary to complications of treatment. Phlebotomy or venesection was performed 
in all patients diagnosed with PV, with a mean requirement of 9 units venesected per patient. The 
time between each venesection was calculated to be on average at approximately 4 months. 
Conflicting opinions appear in the literature regarding venesection. Some authors are of the view that 
venesection alone increases thrombotic risk in the first 3 months and suggest combination therapy to 
avoid this, while others have demonstrated safety in venesecting small volumes at 2 monthly intervals 
(68). Venesection remains the mainstay of treatment in patients with PV.  
 
 
Specific treatment includes cytoreductive therapy with hydroxyurea as the first line agent. It helps in 
suppressing the bone marrow and increasing fetal haemoglobin. In a study of a 100 patients with PV 
who were treated with phlebotomy alone or combined with hydroxyurea, the results indicate that 
hydroxyurea was effective at decreasing phlebotomy requirements without increasing toxicity after a 
mean duration of 69 months of use (142). Hydroxyurea is also capable of alleviating symptoms and 
reducing splenic size as demonstrated in another study where 52% of patients with PMF had a 
reduction in splenomegaly (143). Cortelazzo et al studied the benefits of hydroxyurea in ET patients in 
decreasing the thrombotic events by maintaining a platelet count below 600 x 10⁹/l, and proved that 
it is beneficial in reducing thrombotic complications (72). The majority of the patients in our study 
were initiated on hydroxyurea (69%). It is most commonly used for patients with ET (91% of patients).  
Drugs such as anagrelide were not used in our setting. The ANHYDRET study revealed that anagrelide 
is not inferior to hydroxyurea with regard to thrombotic and bleeding manifestations but conversely 
another study showed that hydroxyurea had better outcomes in reducing complications (72) (76). 
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Busulphan was used in a study of 36 patients with ET and PV who were refractory or intolerant of 
hydroxyurea. The study showed that it is as effective as hydroxyurea, but recommended it as a 2nd line 
agent for patients refractory to hydroxyurea, in view of the toxicity as seen in 30% of the patients (77). 
Interferon alpha or pegylated interferon has also been recommended as a 2nd line therapy in MPN, 
especially in PMF (80). Limited use of both of these agents have been seen in our cohort with only 2 
refractory ET patients having received interferon alpha, while 12 refractory patients with ET having 
received busulphan. This can be attributed to most patients having responded to hydroxyurea and 
only 14 patients showing treatment failure or intolerance to hydroxyurea. Ruxolitinib was prescribed 
to one patient with ET, who was refractory to 3 prior lines of treatment, and was thus put onto a 
clinical trial. Androgen therapy in the form of danazol was prescribed to 5 patients with PMF with 
refractory anaemia. This correlates with the literature where Cervantes et al demonstrated that 
danazol can be useful at an appropriate dose in improving haemoglobin levels (86).  
 
 
In some patients, combination therapy was used. Examples include corticosteroids and hydroxyurea 
in PMF, and hydroxyurea and busulphan in refractory ET. The disadvantage of some of the 
combination therapies are an increased risk of leukaemogenesis as shown in a randomized clinical trial 
of ET patients, where busulphan combined with hydroxyurea showed an increased risk of second 
malignancies of 13% (144).  The median duration of use of hydroxyurea was 226,5 days for ET, and 99 
days for PMF. The reduced amount of days in the PMF group indicates that patients were either 
deemed refractory to hydroxyurea and another agent was added, or due to the late presentations in 
our population with advanced disease, which has a direct impact on poorer survival. 
 
 
More recently, patients with MPN (in particular PMF) have been afforded access to JAK2 inhibitors 
(initially fedratinib and now ruxolitinib). The discovery of JAK inhibitors has revolutionized the way 
MPNs will be treated in the future. Drugs such as ruxolitinib and pacritinib are being evaluated in trials 
to determine whether Ph1 negative MPN can be treated more efficiently, just as tyrosine kinase 
inhibitors in the treatment of CML. Unfortunately due to the lack of funds in the state hospital sector 
in South Africa, these drugs are only available if patients are enrolled in a clinical trial. Therefore, the 
mainstay of treatment in this study remained cytotoxic therapy such as hydroxyurea. 
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The ultimate aim of therapy is to reduce debilitating symptoms, prevent complications of the disease, 
and thus improve quality of life. Analysis of platelet counts were carried out in all ET patients to assess 
the best response to treatment used in our patients with ET. Higher platelet counts increase the risk 
of bleeding and thrombosis and thus treatment aims to reduce this. There is a definite reduction in 
platelet counts in our patients with cytoreductive therapy, with a best recorded median platelet count 
of 466 x 10⁹/l for all the patients with ET. This may not be a complete clinico-haematological response 
of < 400 x 10⁹/l according to criteria by the ELN working group, however it will aid in reducing 
complications (114). The CYTO-PV trial showed evidence that patients with PV with haematocrit levels 
above 0,45 l/l developed more thrombotic and cardiovascular complications (69). More controlled 
haematocrit levels are thus recommended in PV patients. The response to phlebotomy by analysing 
the best haematocrit levels in our patients demonstrated a significant difference. Haematocrit levels 
were lowered with a median best haematocrit level of 0,44 l/l. This correlates with the level 
recommended to reduce thrombotic and cardiovascular complications. 
 
4.8 COMPLICATIONS OF MPN 
Thrombotic complications of MPN are a frequent problem and it has a multifactorial pathogenesis 
(145). Due to the age group that MPN normally present in, these patients generally have other 
comorbidities that also increase the risk of thrombotic and cardiovascular disease. These 
complications generally preclude the diagnosis of MPN, and the search for MPN occurs after they have 
occurred. An increased blood viscosity, altered von Willebrand factor function, dysfunctional platelets, 
are a few abnormalities that lead to thrombosis and bleeding. Thrombotic complications occur in 
about 50% of ET and PV patients (146). Twenty four percent of PV patients and 11% of ET patients 
developed an ischaemic stroke which could be partly due to other risk factors like smoking, diabetes 
mellitus, and hypertension. Venous thrombosis occurred in the form of deep vein thrombosis in 3 
(3,2%) of the patients in our cohort, and pulmonary embolism in another 3 patients (3,2%). In a review 
of 891 patients with ET, 12% of patients developed either arterial of venous thrombosis, these findings 
are similar to our cohort (147).  
 
 
Bleeding was predominantly mucocutaneous (epistaxis; into the skin such as purpura and 
ecchymosis). This was observed in 24% of patients with PMF and 17% of ET patients. This is also similar 
to the literature where a study by Finazzi et al of 1104 patients revealed that twice the number of PMF 
patients compared to ET patients developed bleeding during the course of their disease (148). A total 
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of 6% of patients with ET were diagnosed with portal vein thrombosis, which correlates with a study 
in Europe where 4% of patients developed abdominal vein thrombosis (149). This is a rare occurrence 
but one must suspect MPN if the thrombosis is unexplained. 
Another fatal complication of MPN is their propensity to transform into acute leukaemia. Incidences 
of between 5% to 10% are seen in PV and ET, but the leukaemic transformation of PMF occurs at a 
higher rate of approximately 20% (150). Our study correlates with the literature where only 6% of ET 
patients developed acute myeloid leukaemia (AML), while 14% of PMF patients developed AML. 
Controversy exists regarding the leukaemogenic potential of hydroxyurea. More definite evidence is 
required in this regard, as a predisposition to the development of a malignancy maybe part of the 
natural history of the disease and other factors such the use of alkylating agents, radiotherapy, 
radioactive phosphorus etc. may also be contributory. Two patients (5,7%) developed post ET 
myelofibrosis and 2 patients (11,8%) developed post PV myelofibrosis, which proves it is a rare 
occurrence. 
 
4.9 OUTCOMES OF THERAPY 
The outcomes of therapy in this cohort was assessed by using the revised criteria for myelofibrosis, 
polycythaemia vera, and essential thrombocythaemia, recommended by the ELN and IWG-MRT 
consensus project (112) (113). In our cohort, therapy for MPN is dismal with regard to a ‘’cure’’. Using 
stringent criteria by the ELN, only 5% of all patients achieved a complete response, while 7% of all 
patients achieved a partial response. This may be an indication that these diseases are ‘’chronic’’ and 
rarely curable. Other factors in our patients that portend a poorer outcome include late presentations 
with more advanced stage disease, less stringent adherence to treatment and poor compliance with 
regard to long term follow up. Stable disease is defined as disease that neither improves to a complete 
or partial response, and also does not progress to a more severe disease. A high proportion of patients 
were observed in this group. Fatal disease occurred in 31% of all patients diagnosed with MPN in our 
study, with almost half of all PMF patients’ having demised. Further, no patients received an allogeneic 
stem cell transplantation. 
 
4.10 SURVIVAL 
Survival in patients diagnosed with a MPN has been shown to be moderately reduced for patients with 
PV and ET, but significantly reduced in patients with PMF (151). Factors such as age > 65 years and a 
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haemoglobin level < 10 g/dl are seen as poor prognostic factors in patients with PMF (152). This 
correlates with our study as mean values for age and haemoglobin fall within this range and thus PMF 
patients would be expected to have an unfavourable course of disease. The median survival of PMF 
ranges from 4 to 5,5 years (42). ET has a median survival of 18,9 years in a study at the Mayo Clinic, 
but life expectancy worsens after the first 10 years after diagnosis (118). This could be attributed to 
development of thrombotic complications or transformation to leukaemia. Another study by Tefferi 
et al demonstrated a median survival of 14,1 years for PV, which is less than expected for the normal 
population (61).  
 
 
The survival of patients in our study also correlates with the literature. PMF was shown to have a 
significantly decreased survival as the disease progresses with a 2 year survival of 50% and 5 year 
survival of 40%. ET and PV had much more improved 2 year and 5 year survival times compared to 
PMF. However, similar to the study at the Mayo Clinic, survival worsens as the time progresses with a 
15 year survival of 52% (119). Our findings correlate with the findings in the Western world and 
prognostic factors are similar to that already described. Other comorbid conditions such as 
hypertension, diabetes mellitus, and chronic infections could also impact on survival in our patient 
population. 
 
4.11 CONCLUSION 
Philadelphia chromosome negative MPN in South Africa are generally uncommon diseases which 
typically occur in the 55 to 65 year old age group. It generally has no significant gender predilection. 
PMF is the most common subtype, followed by ET and PV. The common clinical presentation includes 
fatigue, constitutional symptoms and splenomegaly. Presentation to hospital may also be for 
thrombotic events and bleeding manifestations. The mainstay of treatment includes phlebotomy for 
PV, and hydroxyurea for ET and PMF. This therapy was able to produce stable disease in many patients 
but a complete therapeutic response was seen in only a very small number of patients. Complications 
such as arterial and venous thrombosis, bleeding and leukaemic transformation occurred at a similar 
rate to that described in the literature. JAK2 V617F mutation assays became available in 2006, and 
93% of all patients that were tested, proved to have the mutation. Routine testing of this mutation is 
needed in all patients suspected of having a Ph1 negative MPN. JAK2 inhibitors are an emerging 
therapy with potential for use in more of our patients in the future. The prognosis of patients 
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correlates with studies of MPN, as described in the literature. PMF has been shown to have the worst 
survival of the Ph1 negative MPN.       
 
4.12 LIMITATIONS OF THE STUDY 
Due the retrospective nature of the study, aggregated data that was documented in patients’ records 
were relied upon. Not all records were adequately completed and thus information was limited in 
some circumstances. The study was carried out at Chris Hani Baragwanath Academic Hospital, Clinical 
Haematology unit, Department of Medicine, and thus a selection bias may be present. Patients also 
may have been treated by general physicians and thus not referred to the Clinical Haematology unit, 
resulting in an underestimation of the number of possible patients with MPN. Non-compliance as well 
as patients lost to follow up is to be expected at a large institution such as Chris Hani Baragwanath 
Academic Hospital. Even though these limitations were present, the current study provides a fairly 
accurate representation and overview of the Ph1 negative MPN as seen at our public sector hospital 
over a 25 year period.   
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APPENDIX A:   DATA SHEET 
 
 STUDY NUMBER:   
 
AGE:   
GENDER:    
DATE OF INITIAL PRESENTATION:  
 
 
CLINICAL PRESENTATION 
 
HISTORY 
 SYMPTOMS:  PRURITUS:  
                                WEIGHT LOSS:                                             
                          BONE PAIN: 
                                CHEST PAIN: 
                                FEVER: 
                                FATIGUE: 
                                NIGHT SWEATS: 
                                ERYTHROMELALGIA: 
                                BLEEDING: 
                                OTHER:               
  
 
     DRUG HISTORY:  ........................................................................................................................                                    
     
     FAMILY HISTORY: ....................................................................................................................... 
 
CLINICAL EXAMINATION                          
 
      PALLOR:   
      LYMPHADENOPATHY: 
      JAUNDICE: 
             PETECHIAE:               
      PURPURA:                                       
      ECCHYMOSIS: 
      HEPATOMEGALY:   
      SPLENOMEGALY: 
      FUNDAL CHANGES: 
 
 NEUROLOGICAL FALLOUT:    
TIA CVA OTHER DETAILS 
    
 
 
ANY NEW SIGNS OR SYMPTOMS DURING COURSE OF DISEASE: 
............................................................................................................................. ............................... 
 
 
 
NO YES Details (if yes) 
   
   
   
   
   
   
   
   
   
   
NO YES Details (if yes) 
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DIAGNOSIS:    
                                                                                               
                                     
                      ET: 
                      PV: 
                      PMF: 
 
 
TREATMENT:                                                                               
      FOLATE:  
      IRON: 
      ALLOPURINOL: 
      ANTICOAGULANTS: 
      ASPIRIN: 
      PHLEBOTOMY: 
      BLOOD TRANSFUSION: 
      OTHER: 
 
      PLATELET TRANSFUSION: 
NO YES DURATION (IF YES) NO. OF UNITS (IF YES) FREQUENCY (IF 
YES) 
INDICATIONS (IF YES) 
      
 
                         
SPECIFIC TREATMENT INCLUDING DATE OF INITIATION AND TERMINATION: 
                                                                               
 
      HYDROXYUREA:                                           
      ANAGRELIDE:  
      32P: 
      BUSULPHAN: 
      CORTICOSTERIODS: 
      DANAZOL: 
      INTERFERON ALPHA: 
      OTHER: 
 
SPLENECTOMY: 
NO YES DATE (IF YES) INDICATION (IF YES) 
    
 
 
TIME TO PARTIAL RESPONSE FROM INITIAL PRESENTATION DATE: ............................................ 
 
TIME TO COMPLETE RESPONSE FROM INITIAL PRESENTATION DATE: ......................................... 
 
RELAPSE:  
 
 
 
 
N0 YES 
  
  
  
NO  YES DETAILS 
   
   
   
   
   
   
   
   
NO YES INITIATION TERMINATION 
    
    
    
    
    
    
    
    
NO YES DETAILS 
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TRANSFORMATION: 
                                                                                                
                  
        TO ET: 
 TO PV: 
 TO PMF: 
 TO AML: 
 
 
CURRENT STATUS: 
                                                                  
 
COMPLETE RESPONSE:  
PARTIAL RESPONSE OFF TREATMENT:  
PARTIAL RESPONSE ON TREATMENT: 
 
 
DEATH: 
 
        DATE OF DEATH: .............................................................................................................. ................ 
  
CAUSE OF DEATH: ............................................................................................................. ................. 
  
SURVIVAL (DATE OF HISTOLOGICAL DIAGNOSIS UNTIL DATE OF DEATH): ....................................... 
 
LOSS TO FOLLOW UP: 
  
LAST DATE PATIENT SEEN: ................................................................................................................ 
  
STATUS OF PATIENT AT THAT DATE: ................................................................................................. 
 
 
OTHER:  
 
   
 
 
 
 
 
 
 
 
NO YES DATE (IF YES) OUTCOME (IF YES) TREATMENT (IF 
YES) 
     
     
     
     
NO YES DETAILS 
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APPENDIX B:  FLOW CHART OF INVESTIGATIONS 
 
DATE           
WCC           
RCC           
HCT           
HB           
MCV           
PLATELETS           
NEUTROPHILS           
LYMPHOCYTES           
EOSINOPHILS           
BASOPHILS           
MONOCYTES           
BLASTS           
SMEAR 
COMMENTS  
 
NA           
K           
UREA           
CREATININE           
JAK2 V617F           
 SERUM FE           
% SATS.           
TRANSF.           
FERRITIN           
MAGNESIUM           
PHOSPHATE           
CORR. 
CALCIUM 
          
HIV STATUS           
CD4 COUNT 
(IF +) 
          
VIRAL LOAD 
(IF +) 
          
RCF           
VIT B12           
URIC ACID           
PaO2           
O2 
SATURATION 
          
EPO LEVEL           
TOTAL BILI.           
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DIRECT BILI.           
TOTAL PROT.           
ALBUMIN           
ALP           
GGT           
ALT           
AST           
 
 
BONE MARROW ASPIRATE AND TREPHINE: 
  
CELLULARITY: .................................................................................................................................................. 
 ABNORMAL CELLS: .......................................................................................................................................... 
 FOREIGN INFILTRATE: .................................................................................................................................... 
 MEGAKARYOPOIESIS: ..................................................................................................................................... 
 ERYTHROPOIESIS: .......................................................................................................................................... 
GRANULOPOIESIS: ......................................................................................................................................... 
FIBROSIS: ....................................................................................................................................................... 
 
 
CHEST X-RAY: ........................................................................................................................................... 
ABDOMINAL ULTRA SOUND: ................................................................................................................... 
OTHER IMAGING: .................................................................................................................................... 
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APPENDIX C: ETHICS APPROVAL LETTER 
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APPENDIX D: TURNITIN LETTER FROM SUPERVISOR  
 
 
 
